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Although neurodegenerative diseases (NDD) mostly occur in aged people, its onset can also be 
triggered by excessive accumulation of metal ions, particularly copper, iron and calcium in the 
brain which leads to the development of Alzheimer‟s disease (AD). AD affects cognitive 
function in the elderly people. Therefore, there is an urgent need to search and identify new 
sources of anti-AD drugs from natural sources, because available drugs are aggressive and 
have side-effects. According to a neurotoxicology study, chelating or capturing those metals is 
a therapeutic solution. Interestingly, marine microalgae (MMA) are rich in several bioactive 
compounds with neuroprotective, anti-inflammatory and others. Recently, MMA have been 
featured in neuronal-related diseases. This research shows bioactive compounds produced by 





CA) and calcium chelating activities (Ca
2+
CA). Hence, nine different microalgae were 
procured from Necton S.A, Portugal. Three different food graded solvents namely ethyl 
acetate, ethanol and water were used for extraction. The ethanolic extract of Porphyridium sp. 
and Skeletonema costatum were the most significantly bioactive with an IC50 of 1.44 mg/mL 
and 1.95 mg/mL for Cu
2+
CA, 0.942 mg/mL and 0.883 mg/mL for Fe
2+
CA and 0.832 mg/mL 
and 1.02 mg/mL for Ca
2+
CA respectively. The active crude extracts were further partitioned 
into hexane, dichloromethane, ethyl acetate and an aqueous alcoholic by liquid-liquid 
extraction (LLE). Hexane fractions of Porphyridium sp. and S. costatum presented high metal 
chelating activity with an IC50 of 0.461 mg/mL and 0.361 mg/mL for Cu
2+
CA, 0.292 mg/mL 
and 0.263 mg/mL for Fe
2+
CA and 0.451 mg/mL and 0.181 mg/mL for Ca
2+
CA respectively. In 
order to identify the compounds possibly responsible for the activity, the hexane fractions were 
analyzed by GC-MS. About 19 and 22 of compounds were in Porphyridium sp. and S. costatum 
identified, respectively, belonging to 4 classes of metabolites: fatty acids, sterols, alcohols and 
ethers. The most abundant compounds detected were long chain fatty acids and alcohols 
including tetrahydropyranyl ether of citronellol and 3,7,11,15-tetramethyl-2-hexadecen-1-ol. 
The analyzed species exhibited neuroprotective activities in a concentration dependent. Their 







AB = Algal Biomass 
AD = Alzheimer‟s Disease 
Aβ = Amyloid Beta 
Abs. = Absorbance 
APP = Amyloid precursor protein 
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Neuron protection refers to the relative preservation of the structure and function of neurons 
from neurotoxic substances, among others
1
. Neuron-toxicants can inactivate and damage 
neurons, resulting in degenerative diseases which are called dementia
2,3
. Dementia is a brain 
disease that occurs mostly in elderly people due to age related disorder of nerve cell of the 
brain. It leads to chronic progressive mental sicknesses with main characters of disturbing 
memory, orientation, thinking, comprehension, calculation and other essential brain functions 




It has been reported that, over 50 million of people are presently suffering with dementia 
worldwide and approximately 152 million people will be affected in 2050 globally. Every 3 
seconds someone develops dementia somewhere in the world
4
, and it is estimated that 9.9 
million newly cases are arising each year and from which 2.5 million are detected in Europe
3
. 
According to the Alzheimer‟s Disease International Dementia Statistics reports, much of the 
increase is in developing countries having low and middle income, about where 58% of people 
are affected with dementia and it will rise to 68% by 2050
5
.  
The most common cause of dementia is neurodegenerative disease (NDD), which is caused by 
functional loss and sensory dysfunction in the brain; progressive loss or death of nerve cells or 
neurons from central or peripheral nervous system in neurons
6
. Also, dysfunction of synaptic 
function that causes the failure of neurodegenerative networks is due to the accumulation of 
abnormal proteins. These proteins are toxic, insoluble, misfolded and aggregated that are found 
either external or internal cellular in the brain
7
.  
Despite the widespread, prevalence and debilitating effects of dementia, research findings 
reported that, currently there are no cure and reliable testing kits to detect. The underlying 
pathophysiology years before the symptom occurrence are missing for the radically growing 










1.1. Alzheimer’s Disease (AD) 
AD was first clinically recognized by a German psychiatrist, Dr. Alois Alzheimer, in 1915
10
.   
It is an irreversible disease which accounts for 60 to 80% of all progressive degenerative brain 
disorders or dementia. It affects mostly in aged society i.e., above 65 years and develops during 
years to decades before clinical symptoms of dementia emerge, by attacking the brain 
gradually. Thus, the detrimental effects of the aging process are best observed in the brain, 
where irreversibly damaged cells cannot be replaced, that is involved in the development of 
AD
11
. Improved understanding of brain aging pathogenic molecular defects that leads to AD is 
not exceptional
12
. Death usually arises in less than 10 years after of diagnosis. AD affects 
memory, thinking, calculation, learning, orientation, comprehension, language, judgment 
abilities, cognitive capacities and ability to carry out the simplest tasks
10,13
. These symptoms 
are caused by the presence of toxic fibrillar and oligomeric forms of amyloid beta (Aβ) protein 
plaques and tau protein tangles that contribute to the damage of synapses by killing neurons
14
. 
Recently, over 30 million people are living with AD worldwide and this number is projected to 




Still scientists do not understand when and what exactly causes AD. However, there are 
leading hypothesis for the pathology that involves in the development of AD such as (i) 
cholinergic hypothesis (reduction or dis-regulated generation of acetyl and butyl-choline in 
certain part of brain), (ii) amyloid hypothesis (senile plaques composed of aggregated amyloid 
beta protein), (iii) tau hypothesis (intracellular neurofibrillary tangles (NFTs) consisting of 
hyper phosphorylated tau)
16,17,18
 and dyshomeostasis of bio-metals hypothesis
19,20
. All 
hypothesis share similar processes, including: aggregations and misfolding of toxic proteins 
that causes oxidative stress, mitochondrial dysfunction (a breakdown of energy production 
within a cell), which contributes to dysfunction, loss, damage and death of neuronal cells in the 
AD brain. There is an increasing evidence suggesting that dyshomeostasis and neurotoxicity of 
bio-metals contribute in the pathology of AD
17
. 
Approximately 100 billion neurons (each with long and branching extensions) are found in a 
healthy adult‟s brain. Those extensions allow single neurons to form connections with other 
neurons called synapses in which information flow in tiny bursts of chemicals that are released 
by one neuron and detected by a receiving neuron. The human brain contains about 100 trillion 
3 
 
synapses. The synapses enable signals to travel rapidly through the brain‟s neuronal circuits, 
creating the cellular basis of memories, thoughts, sensations, emotions, movements and skills. 
Deposition of Aβ protein plaques outside neurons, contributes to the cells death by interfering 
with neuron to neuron communication at synapses. Also, deposition of an abnormal protein of 
tau tangles inside neurons blocks the transport of nutrients and other essential molecules inside 
neurons in the brain. The presence of toxic amyloid beta and tau proteins activates immune 
system cells in the brain called microglia. However, microglia, try to clear the toxic proteins 
from dead and dying cells. An increase and spread of abnormal and toxic aggregation of 
plaques and tangles of proteins in the brain causes neuronal cell damage and death that leads to 
brain tissue inflammation and shrinkage. This is due to microglia could not keep up with all the 
toxic protein aggregation needs to be cleared. Normal brain function is further compromised by 
the decreased ability of the brain to metabolize glucose, its main fuel. As a consequence, the 
brain of AD patients shrinks compared to a healthy brain due to the loss and damage of 





Figure 1: The healthy brain (left) and AD brain (right) (www.newsnetwork.mayoclinic.org). 
 
 
As neuronal damage increases, the brain can no longer compensate for the changes and then 
patients display cognitive decline such as memory loss or confusion as to time or place and day 
to day activity. Treatments to prevent, slow and stop those changes are not yet available, even 





1.2. Bio-metal Homeostasis Hypothesis 
Bio-metals are important for the healthy body functioning and have a central role in many bio-
chemical pathways, enzymatic activities, mitochondrial function, learning, memory and 
neurotransmission
22
. Mitochondrial functions are the source of energy for brain cells in which 
defects result in deficiency in energy production and increases generation of superoxide and 
hydroxyl radicals. The interaction of superoxide radicals with nitric oxide produces 
peroxynitrite, which irreversibly inhibits mitochondrial respiration, reacts with proteins, lipids, 
carbohydrates and deoxyribonucleic acid (DNA), and causes DNA fragmentation and lipid 
oxidation and, ultimately, radical induced oxidative damage
23
. Imbalanced bio-metals in 
human brain may have multiple origins such as environmental pollution, radiation, genetic 
pattern, drinking water and foods (meat and vegetables), dietary supplements and drugs that we 




 and sleep disorder
26.  
Naturally, cells have controlling mechanisms of bio-metal ions homeostasis. However, 
disproportion or disturbance of those mechanisms of bio-metal ions in their homeostasis result 
in the accumulation of harmful metals, which lead to neuron-degeneration toxicity, loss, 
damage and death of cells. From bio-metals, redox transition metals specially: iron, copper and 
other trace metals are involved in the pathology related neurodegenerative diseases in which 
their levels in the AD patient brain are found to be high. Notably Cu, Fe, and/or Ca may be 
linked directly or indirectly to disturbed homeostasis of ions in neurodegenerative diseases, 
such that new cation chelators can be used as a consecutive therapeutic option
27
.  
The breakdown in the metals homeostatic mechanisms are closely involved in abnormal 
processing of amyloid precursor protein (APP) leading to deposition of beta amyloid peptides 
in the form of senile plaques, along with hyperphosphorylation of tau protein, responsible for 




are able to bind abnormally protein 
components with AD patient‟s brain of different affinities
28
. They promote the processing of 
APP by secretases, senile plaque formation and hyperphosphorylation of tau protein. Thus, 




Based on those assumptions, it has been hypothesized that the dysregulation of a specific metal 
ion leads to the characteristic bio-metal profile. The acceptance and donation of electrons of 
the bio-metals can also contribute in the reactive radical, nitrogen and oxygen species 
5 
 
formation. Therefore, it might be detected in various accumulation or abnormal interactions 
with proteins, lipids or nucleic acids oxidative attack of tissue components
20
. Moreover, if such 
shared bio-metal profiles exist across different neurological disorders, it is possible to correlate 
with the behavioral impairments from the result of imbalanced metal ion homeostasis
28
. 
Furthermore, considering altered concentration of calcium in the brain is also related to the 
development of AD
22
. Gathering all factors together that have a potential to cause AD, Figure 2 
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  Figure 2: Diagram represents bio-metals hypothesis metabolism that causes AD.  
 
Dysfunction, damage and death of cells, 
neurons, neuron transmitters and synapses 
 
Neurodegenerative diseases 
such as Alzheimer’s disease 
















 lead to the accumulation of beta amyloid 


















































Fe2+ / Cu2+/ Ca2+ chelating       
compounds as neuron protector 
Neuroprotective mechanism 
Free iron and copper or weakly bound to metabolites 
Genetic pattern, age, environmental pollution, medications side effect, lifestyle… 
 







Harmful free radicals interact with amyloid beta proteins that increase reactive oxygen species production, auto oxidation of amyloid beta peptide and plaque 
formation outside neurons (B), promote phosphorylation of tau that contributes to synaptic pathology and leads to abnormal accumulation of neurofibrillary 
tangles inside the neuron (A), influx of calcium that damages the membrane (C). Those misfolded beta amyloid protein forms aggregation into oligomers then 
larger structures of beta amyloid plaques and neurofibrillary tangles, which lead to dysfunction, damage, loss and death of neuron. Those proteins aggregation 
have an adverse influence in the neuronal processes, such as communication between the nerve cells. Then once after healthy neurons stop functioning, loss 
and death of connections with other neurons causes AD. Copper and iron, due to their multiple valence states both can react with the molecular oxygen and 
nitrogen that produce reactive oxygen and nitrogen species. The Fenton and Haber-Weiss reaction have significant role in reactive oxygen species production 
and AD pathogenesis. Both iron and copper increase oxidative stress by participating in Fenton and Haber–Weiss reactions, which can lead to the formation 
of harmful reactive species such as super oxide radical, hydrogen peroxide, hydroxyl radical and hydroxyl ion.  
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1.2.1. Homeostasis of copper (Cu
2+
) in AD  
 
Copper is a redox-active metal. It is necessary for brain functioning, mitochondrial activity, 
neurotransmitter biosynthesis, oxidative stress defense and other critical processes for healthy 
brain
27
. Redox-active copper is well known to be correlated with oxidative stress through 
formation of reactive oxygen and nitrogen species
27
 by means of the Fenton and Haber-Weiss 
reaction
13
 (equation 1). Its toxicity is mainly related with its activity as a catalyst for oxygen 
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Haber-Weiss reaction: H2O2 + •O
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OH     ……..……equation (1) 






Reactive oxygen and nitrogen species are originated from the reaction between molecular 
oxygen and unregulated redox active cations such as copper and iron as well. Free radicals are 
any chemical species that contain one or more unpaired electrons. Due to their free state, via 
accepting electrons from other molecules, can easily become a reason to change the structure 
of molecules leading to change in their normal function in the cell. Normally, not all free 
radicals are harmful, some of them are useful in the human body by protecting from disease-
causing microbes being produced by phagocytes which is a specialized blood cells
24
.  
Cells have oxidative defense systems as antioxidants and antioxidant enzymes. They maintain 
and repair the change or harmful effects of the free radicals to keep the equilibrium and flow of 
molecules in the organism. The equilibrium is maintained between activity of antioxidants to 
keep down the levels of free radicals, letting them to neutralize useful biological functions 
without too much damage
31
. When the source of oxidants get high due to malfunctioning of 
free radical production, the body cells of antioxidant defense may get weak and unable to 
process biologically, resulting in oxidative and nitrosative stress
32,33
. Both stresses occur due to 
overproduction of reactive oxygen and nitrogen species in biological systems, or alternatively 
when the defensive species has shortage of enzymatic and non-enzymatic antioxidants. 
8 
 
Oxidative and nitrosative stress can potentially damage important part of cell proteins, 
carbohydrates, cellular lipids, deoxyribonucleic acids that can affect the normal biological 
system
24,33
. Since, human brain due to its high metabolic requirements is known to be an 
aerobically active organ that constitutes 2% of total body mass and consumes about 20% of 
total oxygen when comparing to other body part. Oxidative balance directs and controls the 
brain and this is usually governed by antioxidants that exist in massively higher quantities than 
in any other organ. Therefore modifications in normal oxidative metabolism as observed in AD 
brain, provides strong evidence that oxidative stress plays an important role. In AD 
pathogenesis, redox ion-oxygen radicals are involved in chemical attack, resulting in increased 
free carbonyls, lipid peroxidation adducts, protein nitration, mitochondrial and nuclear 
deoxyribonucleic acids  oxidation adducts
34
.  
Copper plays an important part in the formation of extremely toxic beta amyloid protein in 
senile plaques by facilitating reactive oxygen and nitrogen species causing ultimately neuron 
inflammation in AD brain. Particularly, Cu concentration is raised in amyloid beta protein, 
thereby developing amyloid beta protein oligomerization and neurotoxicity. The alteration of 
copper levels is recognized as an important role in accumulation of tau in the neurons. Cu ions 
are seen in the redox reactions, existing in the neuron fibular tangles.  
Copper is also essential for brain enzymes to control neurotransmitters, for example dopamine, 
neuropeptides and dietary amines. Disruption of copper oxidation in the brain has been related 
to several neurodegenerative diseases, including AD. Copper linked proteins are present in the 
cytosol, nucleus, peroxisome
27
, cytochrome, ceruloplasmin and mitochondrial intermembrane 
space of human cells functioning as enzymatic antioxidant detoxifying superoxide in the brain. 




1.2.2. Homeostasis of iron (Fe
2+
) in AD  
 
The divalent iron is dominant metal ion in the brain, that is also found in beta amyloid 
plaques
27,34,35
. Due to its redox activity, as a result of the Fenton and Haber-Weiss reactions, 
the increase of iron cation in the brain may be harmful and is responsible in increasing the 
oxidative stress generating tissue and neuronal damage. Usually iron accumulates when the 
brain gets aged, that is why it has been well explained as the reason for neurological disorders. 





 and hyperphosphorylated tau protein to induce its aggregation leading to the 
formation of neurofibrillary tangles in AD brain
36
. As a result a symptom such as cognitive 
dysfunction in AD patients recognized. Therefore, chelation therapy has been proposed in a 
situation of iron overload because it can provide constant chelation coverage and is able to 
recover passivity complexes of the metals. Chelators can eliminate the excess or harmful metal 
from the system rendering it proximately harmless and decreasing the late effects
37
.  
1.2.3. Homeostasis of calcium (Ca
2+
) in AD  
 
Calcium is one of the most important cations in brain function, being involved in 
neurotransmission, signal transduction, synaptic plasticity, energy production and regulation of 
proteins network that contributes to synaptic activity
38
. This involves Ca
2+ 
signaling pathways 
in extensive neuronal processing
39
. It has been observed in AD patients that beta amyloid 
plaques can disrupt calcium homeostasis. The impaired ability of neurons to maintain an 




. The fluctuation of Ca
2+
 signaling may 
result in the learning and memory deficits that occur early during the mild AD
39
. Therefore, 
developing calcium chelating compounds can be a better solution to the progressive decline in 
memory and decreased number of neurons in AD
14,39
. 
1.3. Risk factors for AD 
There are numerous risk factors of AD, namely genetic pattern, brain injury and ageing, 
environmental pollution, medications, and lifestyle such as dieting, exercising, sleeping habit 
and others. Those risks for developing AD may differ from person to person.  
Genetic pattern: Having one form of the apolipoprotein E (APOE) gene, which exists in three 




Ageing: Cognitive and memory performance with aging are also considerably related to AD
29
.  
Brain injury: Brain injury is related to reaction of reactive oxygen species with neuronal 
macromolecules mainly from mitochondrial origin which are vulnerable to mitochondrial 
damage by free radicals that may lead to AD
11
. 
Physical inactivity: Not enough physical exercise is indeed related to enhance oxidative stress, 
since oxidative damage is thought to be an early event in AD.  
10 
 




Environmental pollution: Air toxins (e.g. ozone, carbon monoxide, particulate matter, lead, 
sulfur dioxide, and nitrogen oxides) can be a risk factor for AD. Those pollutants speed up the 
accumulation of amyloid beta peptide plaques and neurofibrillary tangles that impair cognitive 
function which are highly associated with AD
11,43
.  
Lack of enough sleep: sleep disorder increases the risk of cognitive impairment
26
. 
Medications and supplements side effects: The consumption of high trans fats combined with 
redox metal and mineral supplements can boost cognitive decline
25
. However, there are 
recommended supplements that prevent AD risk such as omega-3 polyunsaturated fatty acids 




Tobaccos and alcohols: Smoking tobacco and excess consumption of alcohol may substance 
abuse be risk factors of AD
29
. 
Poor diet habit: Diet is essential in biochemical reactions that may harm or benefit brain 
functioning, including nerve cells. A diet rich in antioxidants such as: vitamin E and vitamin C, 
vegetables, fruit juices, and other foods that are rich in folic acid, vitamins, omega-3 PUFAs 
and polyphenols may be helpful in AD prevention
18
.      
Lack of sociable, enjoyable activities and awareness about AD: AD patients quarantine 
themselves from social involvement. Community participation and activities enhance their 
cognitive abilities. Also, systematic cognitive stimulation activities such as puzzles, word 
games, indoor gardening, discussions of the past present reminiscence therapies are 
advantageous to upkeep cognitive ability, mood and behavior. Those practices can help to 
decrease neuropsychiatric symptoms and increase the quality of life of AD patients
44
. Lack of 
awareness about the disease may be  a ground to increase the risk factors of AD
29
.  
1.4. Metal overload chelators and Alzheimer’s disease therapy  
1.4.1. Metal overload chelators 
Different metal chelating agents have been reported as support treatment against to treat cases 
of metal toxicity for several diseases. Among cation chelators triethylenetetramine (TETA), 
nitrilotriacetic acid (NTA) and D-penicillamine (DPA) were used as copper chelators. 
11 
 
Deferoxamine (DFO), deferiprone (L1) and nitrilotriacetic acid (NTA) were mentioned as 
chelators of iron overload
37,45
. Nitrilotriacetic acid (NTA) was considered to chelate calcium 
overload
37
. Additionally, ethylene glycol-bis (2-aminoethylether)-N, N, N′, N′-tetraacetic Acid 
(EGTA) was used in the experimental protocols to chelate calcium
46
. Whereas, ethylene 
diamine tetraacetic acid (EDTA) and meso-2,3-dimercaptosuccinic acid (DMSA) were used as 
a heavy metal chelator
37
. Table 1 shows cation chelators, their activities and adverse effects.  
 
Table 1: Currently used cation chelators adapted from Lawson et al. (2017) 
45
.  
Drug names activities side effects 
DFO iron chelator ophthalmic and auditory toxicity 
   gastrointestinal disturbances 
   affects lung, kidney and nervous system 
   causes hair loss, dryness 
DMSA heavy metal chelator extracellular distribution 
  lipid peroxidation inhibitor gastrointestinal discomfort 
   allergy to skin 
   mild neutropenia 
Deferiprone iron chelator gastrointestinal symptoms 
   headache 
TETA  copper chelator increase urinary excretion 
EDTA metal ions chelator nephrotoxicity, hypocalcaemia 
   allergy, thrombophlebitis 
   congestive heart failure 
   intestinal toxicity, tuberculosis 
DPA copper chelator disrupts immune system 
   anorexia, nausea and vomiting 
   cause neurological problems 
NTA calcium chelator damage to vacuolated cells of proximal tubules 
   blood histology change, auditory toxicity 
  copper chelator cause allergy to skin 
  iron chelator affects kidneys and nervous system 
12 
 
1.4.2. Chemo-therapeutic agents over AD  
There are different approaches that have been used to treat AD; from those approaches 
chemotherapy and non-chemotherapy are the main ones. 
Recently, AD chemo-therapeutic agents used to improve mental functions as cholinesterase 
inhibitors such as tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®) and 
galantamine (Razadyne®) and N-methyl-D-aspartate receptors inhibitor of memantine 
(Namenda®) also combination of (memantine+donepezil) were approved by the U.S. FDA. 
Due to hepatotoxicity of tacrine, was excluded from market since 2012
5,44,
. Those chemo-
therapeutic agents are sourced from alkaloids, piperidine derivatives, carbamates, pyridine 
derivatives various chemical classes, organophosphorus and polyphenols compounds
47
. A 
summary of chemo-therapeutic treatments for AD as cholinesterase inhibitors, are presented in 
Table 2 that describes indications of the stages of the disease and side effects for each 
medication. Mentioned chemo-therapeutic treatments are used to regulate neurotransmitters
48
, 
which are chemicals that transmit messages between neurons to neurons. Those help to delay 
the progression of symptoms of neurocognitive, physical decline and with certain behavioral 
problems. However, those medications do not change the underlying disease process, do not 
prevent and cure, are not effective for all people and their effect terminates after limited 
duration
5,44
. All anti-AD drugs share similar adverse effects such as: dizziness, headache, 












Drug names indications  side effects 
Donepezil mild to moderate atrioventricular block 




Memantine and  donepezil 
mild to severe 
mild to moderate 
moderate to severe 
moderate to severe 
abdominal pain 
atrioventricular block 




1.4.3. Looking for new treatments for AD 
International AD researchers have failed to develop a way to cure or prevent the disease. Under 
study are drug therapies, targeting formation of amyloid beta and tau proteins, loss of synapses, 
and specific neurotransmitters, and non-chemotrophic approach such as physical activity, 
social involvements, dieting, cognitive trainings, in a combined plan. For the treatment of AD 
disease, current pharmacotherapy has troubling side effects, therefore, effective and non-toxic 
new agents are desperately needed
49
. Therapeutics that prevent biological damage from intra 
and extra-cellular metals, must be from safe natural origins, effective, forming stable-
complexes with the metal, have gained attention from most drug designers
37,45
.  
1.4.3.1. Promising natural sources to treat AD  
 
Ever since ancient time medicinal plants play a major role in the controlling of several 
neurological disorders. They are plants providing a huge and energetic source of bioactive 
compounds, some of which can be effective against Alzheimer‟s disease
48
. For example, water 
extract from the seeds of Celastrus paniculatus have been used for the stimulation of the 
cognitive function and improving of learning and memory also considered as antioxidant
50
. 
Sehgal et al. (2012) reported that chloroform-methanol extract from roots of Withania 
somnifera reversed behavioral failures and amyloid beta plaque pathology being the major 
constituents of alkaloids and steroidal lactones as therapeutic compounds
51
. Study shows that 
ethanol extracts of seed and root from P. harmala and A. citriodora have exhibited iron 
chelating activity (63% and 50%) respectively. Those plants were used as traditional oxidative 
stress reducing medicines for symptom improvements in AD
35
.  
Table 3 and Table 4 show the most safe herbs that are used to treat inflammation and 















Table 3: Safe herbs that are used to treat inflammation, forgetfulness and related diseases
5 





Cistanche tubulosa whole  water echinacoside, acteoside treat forgetfulness 
Polygala tenuifolia aerial water 
ethanol 
tenuigenin enhance memory 
antipsychotic agent 
Azadirachta indica leave water unknown anti-inflammatory  
anti-stress  
Coriandrum sativum L. seed water unknown antioxidant  
 anti-inflammatory  






















Ibuprofen, d-penicillamine  
copper and iron 
copper and iron 
anti-inflammatory 
anti-inflammatory 
Bleomycin, ethambutol, thalidomide copper and iron anti-sedative 
Lipoic acid  copper and iron antioxidant  





1.4.3.2. Bioactive compounds from natural sources 
Polyphenols     
More than 8,000 compounds of natural polyphenols have been identified as compounds to 
prevent AD from natural beverages. Polyphenols reveals their antioxidant effect by removing 





Flavonoids are naturally occurring polyphenolic compounds from plants such as: cocoa, fruits, 
vegetables, cereals, tea, and wine. Flavonoids have been extensively used as alternative 
compounds protecting against AD by reducing aggregation of neurotoxic amyloid beta 
peptides into oligomeric
53
. Flavonoids can be classified in to six chemical families such as 
flavonols found in onions, leeks, and broccoli; isoflavones  mainly present in soy and soy 
products; flavones present in parsley and celery; flavanols abundant in green tea, red wine, and 
chocolate; flavanones primarily found in citrus fruit and tomato; and anthocyanidins. Plants 
that are rich in flavonoids enhance memory, cognition and spatial learning
53
. 










) found in some higher plants having positive effects in human health
13
. 
Both protect the cell from oxidative stress, excitotoxicity, neuronal death, are scavengers of 
hydroxyl radical and inhibitors of  lipid peroxidation
13,54
.  
1.5. Marine environment as promising source of new drug leads 
The marine environment encompasses a considerable variety of organisms such as bacteria, 
micro- and macro-algae, vertebrate and invertebrate animals which are a source of new 
bioactive molecules and are still under-exploited. Marine microorganisms produce bioactive 
secondary metabolites whose unique structure is not found in terrestrial organisms
55
. These 
metabolites therefore potentially represent new molecules of interest and include isoprenoids, 
polyketides, peptides, and macromolecules such as nucleic acids, carbohydrates, proteins, and 
lipids. The level of chemical diversity associated with the huge number of environment 





Algae are unicellular, microscopic and phylogenetic diverse group of photosynthetic 
microorganisms including species from different phyla such as Cyanophyta (bluegreen algae, 
cyanoprokaryotes, and cyanobacteria), Chlorophyta (green algae), Rhodophyta (red algae), 
Cryptophyta, Haptophyta, Pyrrophyta, Streptophyta and Heterokontophyta. Microalgae are one 
of the most dominant groups of photosynthetic living organisms. Not only living in aquatic 
medium but also on terrestrial region. Represent an important group of microscopic organisms 
that have the ability to perform photosynthesis, and producing about half of the atmospheric 
oxygen. They vary greatly in their metabolic capabilities and environmental adaptations (light, 
salinity, and temperature)
56,57,58
. Microalgae do not require arable lands for growth; can be 
cultivated in liquid media with high growth rate and productivity. They produce a biomass 
enriched in lipids (60 to 65%), carbohydrates, proteins and fibers (33 to 50%)
59
. Their 
revelations of compounds with new and unique structures make them attractive in terms of 
biological functions for different food, animal feed and aquaculture. They produced by 
industries in various pharmaceutical formulations such as cosmetics, textiles, biofuels and 
biofertilizers
53,56
. Table 5 illustrates isolated bioactive compounds from microalgae, and their 
promising effects in human health and applications. 
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Table 5: Bioactive compounds isolated from microalgae 
Microalgae bioactive compounds health promising effects applications   ref. 
Haematococcus 
pluvialis 
astaxanthin, lutein, zeaxanthin 







phenols, vitamin E 








Chlorella  sp. carotenoids, sulfated polysaccharides 

















    
56,60 
 
Nannochloropsis  sp. eicosapentaenoic acid antioxidant 












Isochrysis  sp. lipids, fatty acids, carotenoids antioxidant 







Tetraselmis  sp. hexadecatrienoic acid antioxidant 









1.6. Search for new neuroprotective compounds from microalgae 
It was already mentioned in section 1.2.1 and section 1.2.2 that, redox metals act as catalysts for 
reactive oxygen and nitrogen species production.  Due to their loosely bound of electrons of 
their outer layer and capacity to exist in more than one valence, can contribute to the 
pathogenesis of AD. Several reports have established that free radical scavenging mechanisms 
via metal chelation in the brain are therapeutic targets for the management of AD
63
. Extracts of 
microalgae like H. pluvialis, Nannochloropsis sp., Neochloris oleoabundans, T. chui, P. 
tricornutum, Chlorella minutissima and Stigmatophora, Rhodomonas salina and Chaetoceros 
calcitrans exhibited ferric iron, copper, lipid peroxidation, and neuronal damage reducing 
antioxidant activity. Antioxidant activities of marine algae have been determined by various 
methods such as 1, 1-diphenyl-2-picryl hydrazyl (DPPH) radical scavenging, 2, 2′-azinobis-3-
ethylbenzo thizoline-6-sulphonate (ABTS) radical scavenging, singlet oxygen reducing activity, 
lipid peroxide inhibition, superoxide and hydroxyl radical scavenging assays. Having PUFAs, 
flavonoids, sterols, carotenoids and phenolics as potent metal chelators, scavengers of free 
radicals,  inhibitors of Fe
2+
- induced lipid peroxidation and protein oxidation
53
. These chelators 
are useful for treating AD by protecting the cells from oxidative and nitrosative damage
63
. 
Compounds feature such as: branches, molecular weight, conjugational exposure of the rings 
and π bonds in the metal chelators make them more capable in capturing and inhibiting reactive 
oxygen and nitrogen species formation. For example, it has been stated that the number of 
hydroxyl groups on the ring structure is associated with the effects of reactive oxygen and 
nitrogen species dominance
37
. Thus, indicates ways of developing new compounds from marine 
algae of various organisms that prove to be useful candidates for protecting the brain cell 
against any oxidative and nitrosative stresses degradation. It may lead to the development of 
effective neuroprotective agents in order to slow down the progression of neurodegenerative 
diseases such as Alzheimer‟s
53,63
. 
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) 
Omega-3 PUFAs such as α-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid (DHA) 
have been publicized to be effective in preventing Alzheimer‟s disease and inflammation. Those 







Sterols are organic compounds known as steroid alcohols (have hydroxyl group) and subgroup 
of the steroids that contain four fused cycloalkane rings
13
. Sterols and phytosterols have 
antioxidant and hypocholesterolemic properties
64
. Sterols provide protection against oxygen 




 and regulate 
membrane fluidity of the cells
59
. Microalgae, Skeletonema sp. have sterols in which cholesterol 
being the major form
56
 and campesterol, stigmasterol, ergosterol and fucosterol as minor
13
 that 
are capable to reduce the risk of heart and coronary diseases
56
. 
Long-chain halogenated compounds 
Volatile long-chain halogenated compounds have shown biological activities such as anti-
inflammatory and neuron protection
59
. Exploring compounds from microalgae with metal 






















2. OBJECTIVES  
The main objective of this study was to search for new compounds with neuroprotective 
capacity in natural extracts from marine microalgae. To achieve this, several specific objectives 
were underlined: 
  To select amongst different extracts prepared from several microalgae species 
(Haematococcus pluvialis, Isochrysis sp., Nannochloropsis sp., Phaeodactylum 
tricornutum, Porphyridium sp., Skeletonema costatum, Spirulina sp., Tetraselmis 
chuii and Tetraselmis sp. CTP4) the one‟s with highest capacity to chelate metals 
such as iron, copper and calcium relevant for neurodegenerative diseases; 
  To obtain an active fraction with a more reduced number of compounds via bio-
guided fractionation of the selected extract; 
  To chemically characterize and tentatively identify bioactive compounds in the 





















3. MATERIALS AND METHODS  
3.1. Chemicals and reagents  
All solvents and chemicals used for extraction, preparation, fractionation, derivatization and 
were ofmetal chelating activity assays  analytical grade. These included: ethanol (EtOH), n-
hexane, ethyl acetate (EA), dichloromethane (DCM), methanol (MetOH), acetyl chloride and 
dimethyl sulfoxide (DMSO) were purchased from VWR International (Leuven, Belgium). 
Ultrapure, Type 1 water was obtained using a Milli-Q® Water Purification System and sodium 
sulphate anhydrous (Na2SO4) was from (Darmstadt, Germany). For characterization by GC-MS, 
n-hexane GC grade was used (VWR International, Leuven, Belgium).  
For copper chelating activity assay, sodium acetate (C2H3NaO2), ethylenedinitrilotetraacetic 
acid disodium salt dehydrate (C10H14N2Na2O8·2H2O) (EDTA), pyrocatechol violet (C19H14O7S) 
and acetic acid (CH3CO2H) were from Sigma (Steinheim, Germany) while copper (II) sulfate 
pentahydrate (CuSO4·5H2O) was obtained from VWR International (Leuven, Belgium).  
For iron chelating activity assay, iron (II) chloride tetrahydrate (FeCl2·4H2O) was from VWR 
International (Leuven, Belgium) and ferrozine (C20H12N4Na2O6S2) was obtained from Acros 
(Geel, Belgium). For calcium chelating activity assay, ammonium chloride (NH₄Cl), ammonia 
(NH3) and calcium carbonate (CaCO3) were purchased from Merck (Darmstadt, Germany). 
Ethylene glycol-bis (2-aminoethylether)-N, N, N′, N′-tetraacetic acid (C₁₄H₂₄N₂O₁₀) (EGTA) 
and o-cresolphthalein complexone (C32H32N2O12)) were from Sigma (Steinheim, Germany) and 
hydrochloric acid (HCl) was from Fischer Scientific (Loughborough, UK).  
3.2. Experimental design  
For the evaluation of the neuroprotective capacity, nine species were selected: Haematococcus 
pluvialis (Chlorophyta); Isochrysis sp. (Haptophyta); Nannochloropsis sp. (Eustigmatophyta); 
Phaeodactylum tricornutum (Bacillariophyta); Porphyridium sp. (Rhodophyta); Skeletonema 
costatum (Bacillariophyta); Spirulina sp. (Cyanobacteria); Tetraselmis chui (Chlorophyta) and 
Tetraselmis sp. CTP4 (Chlorophyta). Those species are industrially cultivated meaning that 
abundant amounts of biomass can be made available from the producers upon request. This can 
be a main advantage when high amounts of pure active compounds are needed for structure 
characterization, for example, as secondary metabolites are usually produced at very low 
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concentrations. Species of microalgae and extraction solvent have great effects on the yield and 
type of extracted bioactive compounds. We selected water, ethanol and ethyl acetate as 
extracting-solvents.  
Water was selected because of its high polarity (PI = 10.2)
65
 availability, being non-toxic, non-
flammable, environmentally friendly and generally a greenest solvent than any other
66
. It has 
the potential to extract polar compounds such as peptides, carbohydrates and others from 
microalgae
67
. Ethanol was selected as the extracting-solvent for its low toxicity, being also 
and isenvironmental friendly. It is less polar (PI = 5.50)
65
 than water  expected to provide high 
yields of polar compounds and some non-polar bioactive compounds such as polyphenols, 
vitamins and some carotenoids with highest metal chelating activities. Ethyl acetate (EA) is 
widely used in food industry as artificial aroma or flavoring for making cakes and ice creams 
and is a source of fragrance in perfumes industries
68
. EA is also classified as environmentally 
friendly, renewable and less-toxic. It is less polar (PI = 4.40)
69
 than water and ethanol. 
Therefore, extracts of EA are expected to extract less polar compounds from algal biomass. 
formulate aAfter extraction, their residue can be used to  source of active ingredients with 
potential applications in feed, food or dietary supplements, fertilizer, bio-colorant for food 
drinks
70
, textile and paper industries
71
, and used for biofuel generation
72
 due to safety for 
environment
73
. Dimethyl sulfoxide (DMSO) was selected as a solvent to dissolve extracts (both 
polar and non-polar compounds) due to its high solubility (103.7 mg/mL in water) at room 




Extracts were firstly tested at a concentration of 10 mg/mL as preliminary screening to identify 






) chelating activity. 
Values of metal chelating activity, MCA > 60% were considered worthy enough for further 
analysis to determine the mean chelation concentration IC50. Logically, if the extract‟s activity 
at 10 mg/mL is less than 50% it could not be expected to keep active when the concentration 
decreased, rather the activity decreased or remained the same, however, the activity could not be 
enhanced, otherwise, it had to be active at least more than 50% of total activity at 10 mg/mL. 
IC50 means the concentration of chelator required to chelate 50% of free metal ions
76
. In this 
study, extracts with less IC50 values (IC50 < 2 mg/mL) were considered active enough for bio-
guided fractionation. Fractions with the lowest IC50 are called the highest in activity
76
.   
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To identify the bioactive compounds in the fractions, Gas Chromatography coupled with Mass 
Spectroscopy (GC-MS) was used. 
3.3. Algal biomass (AB)  
Freeze dried powdered algal biomass was kindly provided by NECTON S.A.; (Olhão, 
Portugal), a company established in 1997 that develops its activities in the marine 
biotechnology field having specialized in the production and commercialization of microalgae. 
Before conducting all experiments, samples were stored in the dark inside a desiccator at room 
temperature.  
 
Figure 3 presents micrographs of microalgae species used in this study.   
             
 
             
 
             
Figure 3: Micrographs of microalgae species used in this study  
Haematococcus pluvialis (Hp) (1) (source: Kavitha et al. (2015));  
Isochrysis sp. (Isp.) (2) (source: https://algaeresearchsupply.com); 
Nannochloropsis sp. (Nsp.) (3) (source: https://algaeresearchsupply.com);  
Phaeodactylum tricornutum (Pt) (4) (source: https://mycocosm.jgi.doe.gov);  
Porphyridium sp. (Psp.) (5) (source: https://algaeresearchsupply.com);   
Skeletonema costatum (Sc) (6) (source: www.eoas.ubc.ca);   
Spirulina (Ssp.) (7) (source: https://vnibioscience.en); 
Tetraselmis chui (Tc) (8) (source: https://ars.els-cdn.com); 
Tetraselmis sp. CTP4 (CTP4) (9) (source: Pereira et al. (2015)). 
1 
9  8 7 




3.4. Preparation of extracts  
One gram of dry powder algal was mixed with 40 ml of solvent (ethanol, ethyl acetate or water) 
(1:40, w/v) and stirred (200 rpm) at room temperature (RT) under contentious string using a 
platform shaker (IKA, VMS-A, VWR, Leuven, Belgium) overnight (18 hours). The mixture 
was centrifuged at 2,500 rpm, for 10 minutes at RT (Thermo Scientific™ ST16R TX-400 
Centrifuge, Portugal). The pellet was re-extracted twice more with the same solvent following 
the same procedure. Supernatants were combined and filtered through Whatman no. 4 filter 
paper pore size (10-12 µm) followed by a 0.45 μm syringe filter (Prat Dumas, France). Later, 
filtrates were concentrated using a rotary evaporator (IKA, RV10 digital, Staufen, Germany) at 
40°C under reduced pressure (Table 6) and solvents evaporated under a gaseous nitrogen stream 
flow until complete dryness
77
. Table 7 shows dry yield of extracts from algal biomass. The 
dried extracts were dissolved in dimethyl sulfoxide (DMSO)
78
 at a concentration of 20 mg/mL 
as a stock solution and stored in amber glass vials
67
 in order to protect them from light exposure 
(Ossila enabling materials science Ltd, Sheffield, UK) and were stored at -20°c
79
. A 
summarized flow of extract preparation from algal biomass is presented in Figure 4. 
 









polarity index ref. 
 
Ethanol C2H6O 46.0 175 5.20 
65,80
 
Ethyl acetate C4H8O2 88.1 240 4.40 
69,81
 


















                                                                           













                                                                                                        
     
             
    
  
                                                              
  
                                                                     
                   














Figure 4: Flow chart of extract preparation from algal biomass 
 
3.4.1. Yield of extracts 
 
The yield was expressed as percentile yield of dried extract (%) with respect to total mass of 
algal biomass used and multiplied by 100
82,83
 (equation 2). 





                      
Concentrating  
Stock preparation  
 Dissolving 1 mg of dry extract with 20 mL 
of DMSO at  room temprature                      
Dried powdered algal biomass from NECTON S. A. 




2,500 rpm, 10 min, at RT 
 
 
Filtering at RT 
 
Concentrating in rotary evaporator 
at 100 rpm, 40 °C       
 
Nitrogen gas drying for complete dryness 
 
 
Storing at -20 °C 
 
Complete drying  




𝑌𝑖𝑒𝑙 𝑜𝑓 𝑑𝑟𝑖𝑒𝑑 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 (%) =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑖𝑒𝑑 𝑒𝑥𝑡𝑟𝑎𝑐𝑡
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑙𝑔𝑎𝑙 𝑏𝑖𝑜𝑚𝑎𝑠𝑠
× 100………………… equation (2) 
               Table 7: Dry yield extracts from algal biomass 
Algal biomass extracting-solvents yield of dried extracts (%) 
H. pluvialis ethanol 3.19 
 ethyl acetate 3.33 
 water 2.23 
Isochrysis sp. ethanol 1.01 
 ethyl acetate 1.72 
 water 4.57 
Nannochloropsis sp. ethanol 7.32 
 ethyl acetate 2.62 
 water 11.6 
P. tricornutum ethanol 1.54 
 ethyl acetate 1.39 
 water 1.51 
Porphyridium sp. ethanol 1.17 
 ethyl acetate 1.01 
 water 1.49 
S. costatum ethanol 1.09 
 ethyl acetate 1.22 
 water 5.89 
Spirulina sp. ethanol 11.8 
 ethyl acetate 1.71 
 water 2.12 
T. chui ethanol 2.01 
 ethyl acetate 1.02 
 water 11.7 
Tetraselmis sp. CTP4 ethanol 3.01 
 ethyl acetate 9.8 




3.5. Assays for metal chelating activity 
Prior to calculate percentage of metal chelating activity of extracts, the average absorbance of 
color control was recorded to correct the absorbance of the extract. Since, the extracts are 
colored and their absorbance could interfere at the same wavelength
84
, their absorbance was 
subtracted from the absorbance of the chromogenic complex formed between cation and 
chromogenic reagent, the corrected absorbance was calculated by subtracting the absorbance of 
color interference due to average algal (color/pigment) from absorbance of algae‟s color, and 
disturbance of color due to cation-chromogenic reagent complex and presence of chelating 
agents (equation 3). 
 
 Corrected absorbance = 𝐴𝑏𝑠.(𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 𝑎𝑛𝑑 𝑟𝑒𝑎𝑔𝑒𝑛𝑡𝑠  − 𝐴𝑏𝑠.𝑜𝑓 𝑐𝑜𝑙𝑜𝑟 𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 ………....equation (3) 
 
Metal chelating activity of algal extracts was calculated using corrected absorbance with 
respect to the average Abs. (absorbance) of negative control.   
Percentage of metal chelating activity ( %) is expressed following the formula
78,83
 of equation (4). 
 
Metal chelating activity (MCA) (%) = 
𝟏𝟎𝟎−( 𝐴𝑏𝑠.𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑×𝟏𝟎𝟎)
𝐴𝑏𝑠.𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
      ..........................................equation (4)  
Where, metal chelating activity is expressed in percentage (%),  𝐴𝑏𝑠.𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 corresponds to the 
corrected absorbance of each extract obtained having in mind the above (equation 3), and 
𝐴𝑏𝑠.𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  is the average absorbance of negative control.  
It was decided that values obtained using (equation 4) having percentage of metal chelating 
activity (MCA) greater than 60%, (MCA > 60%) would be selected to determine IC50 (mg/mL).  
The IC50 (mg/mL) values were then analyzed using Graph Pad Prism software version 7
85
.  A 
dose-response inhibition curve was obtained by means of non-linear regression, then fitting to a 
normalized response model with variable slope. The x-intercept of the plot stands for log (IC50), 
IC50 values are calculated from antilog of the x-intercept and y-intercept of the plot stands for 
metal chelating activity in percentage. Further, the correlation coefficient (R
2
) measures the 
linear association how good the model fits with experimental data. The closer to the R
2 
= 1 










The ability of extracts to chelate free Cu
2+
 was determined using pyrocatechol violet (PV) as 
chromogen according to Ismael et al. (2016)
78
 with some modifications. In a flat-bottom 96-well 
polystyrene microplate (300 μL/well), 164 μL of 50 mM aqueous sodium acetate a slightly acidic 
(pH = 6.0) buffer solution and (30 μL) of (10 mg/mL in DMSO) of extracts were mixed with 100 
μL of CuSO4·5H20 (50 μg/mL, w/v in ultrapure water) and 6 μL of 4 mM PV dissolved in the 
buffer. In the absence of copper chelating compounds Cu
2+ 
reacts with pyrocatechol violet 
forming a dark-colored complex of Cu-PV with a maximum of absorbance at 632 nm
86
. In the 
presence of copper chelating compounds Cu-PV complex formation is inhibited, and the solution 
turns yellowish (Figure 5). Therefore, Cu
2+
 chelating compounds can be estimated by the 





was calculated as percentage of chelation and as IC50 values (mg/mL) relative to a blank 
(negative control, C
-
), which contained 30 μL of DMSO in place of the extract. The absorbance 
was corrected using color controls containing just extract and buffer, to eliminate interferences 


























                                                        pH
 
= 6.0  
 Cu
2+
 chelating compounds + Cu
2+
               Cu
2+
chelating compounds-Cu + 2H+.....equation (5) 
                    
…..equation (6) 
Pyrocatecol violet (PV)                                    Cu-PV complex 
 
                  Psp.C Psp.H Psp.DCM Psp.EA Psp. aqueous ethanol 
        C
-
     C
+
                                               ScC ScH ScDCM ScEA Sc aqueous ethanol 
      
  










    
 
                                                                                                               
                                                                                                             
 
Figure 5: Color change due copper chelating compounds 
See after section 4.1. In the copper-binding assay using pyrocatechol-violet as chromogen agent, 
virtually, copper chelating compounds react with Cu
2+
 (equation 5) forming complex that inhibits the 
complex between PV and Cu
2+ 
(equation 6). The 96-well micro plate contains the crude of ethanolic 
extract of Porphyridium sp. (Psp.C) and S. costatum (ScC) and their fractions of (hexane, 
dichloromethane, ethyl acetate, aqueous ethanol) at 10 mg/mL. The first 2 columns of the plate are 
contains solution of negative (C
-



















The capacity to chelate Fe
2+
 from the extract was determined by measuring the formation of the 
iron-ferrozine complex as designated in the litrature
13,78
 with slight modifications. A 30 μL 
extract were mixed with 200 μL of sodium acetate buffer (pH = 4.9) in 96-well micro plates. 
Then, 30 μL of FeCl2•4H2O (0.1 mg/mL, in ultrapure water) solution was added and incubated 
after stirring at room temperature
87
 for 20 min. A 12.5 μL solution of ferrozine (40 mM) was 
then added and the mixture was stirred and incubated for 10 min at room temperature. In 
slightly acidic medium, iron reacts with ferrozine making Fe-ferrozine pink-colored complex 
(Figure 6). However, in the presence of iron chelating compounds, the formation of the Fe-
The estimated ferrozine is disrupted which leads to a decrease in the color and absorbance
86
. 
binding ability of the extracts was detected spectrophotometrically at λ = 562 nm using a 96-
well micro plate reader at room temperature. Therefore, the higher absorbance at λ = 562 nm is 
due to the Fe-ferrozine complex, while the lower absorbance corresponds to an increase in iron 
chelating compounds that existed in the reaction mixtures
88
. DMSO (30 μL) replaced the extract 
as a negative control (C
-
) to express the percentage of Fe
2+
 chelation ability of extract using 
(equation 4) that was mentioned in section 3.5 and as IC50 value (mg/mL). Color control (30 μL 
and 270 μL of buffer) was used to correct the absorbance for unequal color between extracts 
and complex formations. These activities were compared with the chelating activity of synthetic 




















                                                       p
H
 = 4.9 
Fe
2+
 chelating compounds + Fe
2+
                 Fe
2+
 chelating compounds-Fe + 2H
+ 
 .…equation (7)      
 
 
….…equation (8)      
                                                                                  
                            Ferrozine                            Fe-ferrozine complex  
 
 
       1     2      3     4      5      6     7      8     9    10   11   12 
 
Figure 6: Color change due to iron chelating compounds 
See after section 4.2. Iron chelating compounds bind with Fe
2+
 (equation 7) and ferrozine bind with Fe
2+ 
(equation 8). A 96-well micro plate of column 1 and column 2 referring (C
- 
showing pink color due to 
Fe-ferrozine complex and C
+
 viewing colorless is due to Fe
2+
 was already chelated by synthetic chelator 
(EDTA, 1 mg/mL), resulting no Fe
2+
 leftover to bind with ferrozine) respectively. Column 3,5 and 7 are 
solutions of color control and 4,6,8 contain reagents + extract of Porphyridium sp. of water, ethanol and 
ethyl acetate respectively; columns 9 and 11 are solution of color control  and 10 and 12 reagents + 
ethanolic extracts of H.  pluvialis and Spirulina sp. respectively, n=8. 
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The ability of algal extracts to chelate excess Ca
2+
 was performed by measuring the formation 
of the Ca
2+
 with o-cresolphthalein complexone (OCPC)
78,89
. In 96-well micro plates, 50 μL of 
extract and 75 μL ammonia-ammonium chloride buffer (pH = 9.96) were diluted with 125 μL 
ultrapure water. Then 30 μL of prepared Ca
2+
 standard (aqueous of 0.5 mM CaCO3 and 1mL 
1M HCl) and 20 μL of 0.47 mM o-cresolphthalein complexone were homogenized with the aid 
of a 300 μL micropipette and the change in color due to Ca-OCPC complex formation was 
observed. When calcium reacts with OCPC, acidity of the mixture increases by the presence of 
ionizable protons causing their ionization to develop color. It is due to calcium ion is bounded 
by the imino diacetate, two carboxylic oxygen atoms, imino nitrogen and the phenolic oxygen 
with in o-cresolphthalein complexone that forms calcium-OCPC eight co-ordinate which is pale 
pink in color
89
 (Figure 7). In the presence of calcium chelating compounds, Ca
2+
 reaction with 
OCPC is inhibited as well as the pink complex color
90
 (Figure 7) gets disrupted. The presence 
of calcium chelating compounds thus decreases absorption at wave-length of λ = 575 nm. The 
change in color was measured on a micro plate reader (Biotek Synergy 4). A 50 μL of 1 mg/mL 
of EGTA was used as the positive control due to the ability of higher affinity for Ca
2+
 than other 
extracts‟ colorcations
78
. Absorbance due to the  was adjusted by color control solution. Results 
were expressed as percentage of chelation ability of extract relative to a negative control 50 μL 




















                                                         pH = 9.6        
Ca
2+
 chelating compounds + 2Ca
2+
               Ca
2+
chelating compounds-Ca + 2H
+ 
 ....equation (9) 
 
.....equation (10)                                                
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Figure 7: Color change due to calcium chelating compounds 
See after section 4.3, calcium chelating compounds react with calcium which form a complex (equation 
9) and assay using o-cresolphthalein (OCPC) complexone as chromogen which forms OCPC-Ca 
complex (equation 10) as could be observed as pink color, and a 96-well micro plate containing the IC50 













3.6. Partition of active crude extracts by LLE  





, dichloroethane, isopropanol, propanol, and water
92





, isooctane benzene, toluene, chloroform, diethyl 
ether
91
 and dimethyl ether
92
 to extract and purify active compounds from different extracts. 
Usually liquid-liquid extraction (LLE) uses less expensive equipment, small solvent 
consumption, resulting  in pollution prevention and high extraction yield, is fast, and easy to 
operate
91,92
. There are different families of high-value biochemical compounds present in the 
algal biomass identified from algal extracts using LLE as fractionating techniques such as fatty 
acids, carotenoids
93
, alkanes, terpenes, alcohols, aldehydes
94
 and others have been also 
identified that are responsible in decreasing the exposure of neurological disorder disease, 
inflammationmental illness and 
94,95
. Therefore, in order to fractionate extracts with 
neuroprotective ability, LLE was chosen over other known techniques such as column 
chromatography with silica gel (silicon oxide) and/or alumina (aluminum oxide) as a stationary 
phase and organic solvents as eluent (mobile phase)
96
 to fractionate extracts. Because 
chromatography is time consuming, LLE is preferred as a fractionation method.  
The typical apparatus used for LLE is a separatory funnel. During the LLE extraction, 
hydrophilic components are more soluble in aqueous whereas hydrophobic compounds can be 
extracted from aqueous phase using organic solvents with different polarity having the principle 
of like-dissolve-like
91,97
. Position of the phases in the separating funnel depends on their 
density. The aqueous phase is usually on the bottom as water is denser than most organic 
solvents such as ethyl acetate and n-hexane whereas halogenated solvents for instance 
dichloromethane (DCM) and chloroform at the bottom of water (Figure 7C and Figure 7D). In 
this study, two active ethanol extracts of Porphyridium sp. and S. costatum were selected for 
fractionation. Selected extracts were fractionated by LLE using three solvents by increasing 
polarity such as n-hexane (PI=0.10)
98
, dichloromethane (PI = 3.10)
99
 and ethyl acetate (PI = 
4.40)
69
. Four active fractions were obtained to be further tested for neuroprotective capacity.  
For the fractionation, 3.50 g of crude extract was dissolved in 150 mL of ultrapure 
water+ethanol (80:20; ultrapure water+ethanol, v/v) and poured in to a clean 500 mL sized of 
separatory funnel. The mixture of the ethanol extract with the water increases the polarity of the 
mixture making it relatively immiscible with the organic solvents selected
96
. After that, 
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performed using 50 mLconsecutive extractions were  of solvents with increasing polarity, 
starting with hexane (a non-polar solvent). The mixture was gently shaken to avoid emulsions 
and the vapor pressure of the solvents was released after each round of shaking by opening the 
stopcock
100
. The funnel was rested until complete separation of the two phases. The bottom 
phase (layer) was removed into a clean reagent bottle and the top layer poured out from the top 
of the funnel in a clean labeled reagent bottle
100,101
. The aqueous layer was introduced again into 
the funnel and then two more consecutive extractions with hexane (50 mL) were obtained. The 
process was repeated with dichloromethane, ethyl acetate then finally ultrapure water-ethanol 
fraction. Four obtained fractions of (hexane, dichloromethane, ethyl acetate and ultrapure water-
ethanol) were collected carefully (Figure 8D). Hexane, dichloromethane and ethyl acetate 
fractions were dried over anhydrous sodium sulfate in order to remove remaining moisture 
solvent and filtered with by Whatman no. 4 filter paper pore size (10-12 µm) and afterwards by 
0.45-μm syringe. All fractions were then concentrated under reduced pressure at 40 °C using a 
vacuum rotary evaporator (Figure 9A) then transferred to pre-weighed and labeled dark-brown 
vials then dried under a gentle nitrogen flow (Figure 9B). Table 8 represents values of dry yield 
of fractions in percent after fractionation. All fractions were then dissolved in dimethyl 
sulfoxide (DMSO) to obtain a stock solution at a concentration of 20 mg/mL. Crude extract and 
portioned fractions namely hexane, dichloromethane, ethyl acetate and alcoholic aqueous were 
re-tested for neuroprotective capacity in terms of metal chelating activity as described in section 
3.5.1, 3.5.2 and 3.5.3. The most active fraction was chemically characterized by Gas 
Chromatography-Mass Spectrometry (GC-MS) to tentatively identify the major compounds 










Figure 8: Partitioning of active crude extracts by LLE 
Through the LLE, solvents with used; dried increasing polarity were extract was first dissolved in 
ethanol and water (20:80, v/v) and transferred in to a separating funnel then rested for 15 min (A). 
Next, hexane was added, funnel was gently shaken and two phases were formed rested in the ring for 
an hour to settle, hexane (organic) fraction in the upper part forming organic phase and aqueous 
fraction (water and ethanol) in the bottom part due to the water density (B) Then, aqueous fraction was 
introduced again into the funnel and extracted with dichloromethane, mixed well and settled for an hour. 
Then stopper removed and covered by aluminum foil (C). S ince  dichloromethane has higher density 
than water, it rested to the bottom, while aqueous fraction formed upper layer (C and D; D the second 
round after dichloromethane addition and showing the tip of funnel nestled in the reagent bottle). Lastly, 
extraction of aqueous phase was done with ethyl acetate, producing two fractions, ethyl acetate (organic 
phase) in the upper layer and water with ethanol (ethanolic aqueous phase) in the bottom layer (E). In 
order to lower the loss of fractions the procedure was repeated three times
96
. Afterwards, all obtained 
fractions were filtered through anhydrous Na2SO4 to remove water remaining from organic fractions (F). 
Finally, all fractions were collected (G) and solvent was removed (through rotary evaporating and 
nitrogen gas stream flow). 
 
                             Figure 9: Solvent removal process 
After LLE, solvents of  obtained organic fractions were concentrated  in  a rotary evaporator at 40℃,  
100 rpm and under controlled  pressure (A); afterwards remained solvent was evaporated using nitrogen 
gas stream for complete dryness of fractions in pre-weighted dark vessels at room temperature (B). 
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                 Table 8: Dry yield of fractions (%) 
Algal species fractionating-solvents dry yield of fractions (%) 
Porphyridium sp. hexane 6.66 
 dichloromethane 4.67 
 ethyl acetate 5.91 
 aqueous ethanol 10.1 
S. costatum hexane 11.2 
 dichloromethane 20.7 
 ethyl acetate 9.51 





                                                                                                      
   
   
                                                                           
   
                                                                  
 
                                                                                                        
                  
                          
 
                                    
                                                                                                                                       
 
                                                                                             
            
                
 
                                                                                                                  
 
                           








Figure 10: Flow chart for bio-guided fractionation (LLE) 
Step 4b. Hexane (organic; upper layer) Step 4a. Aqueous ethanol (aqueous; bottom layer) 
Step 4c. Hexane fraction 
obtained 
Step 5a. Dichloromethane; bottom layer Step 5b. Aqueous ethanol; upper layer 
Step 5c. Dichloromethane fraction 
Step 6a. Aqueous ethanol; bottom layer Step 6b. Ethyl acetate; upper layer 
Step 6c. Ethyl acetate fraction 
Step 3. Aqueous ethanol solution 
Step 4g. Hexane fraction obtained totaling (150 mL) Step 4f. Aqueous ethanol solution 
Step 5g. Aqueous ethanol 
solution 
Step 5f. Dichloromethane fraction obtained totaling (150 mL) 
 
Step 1. Psp.EtOH and ScEtOH (bioactive crude extracts, 3.50 g of each) 
Step 2. Extracts dissolved in separatory funnel (120 mL ultra-pure water and 30 mL ethanol) 
Step 4. Fresh n-hexane organic solvent (50 mL) was added 
Step 4d. &Step 4e. Hexane (50 mL) was added twice time, then Step 4a., Step 4b. and Step 4c. repeated 
Step 5. Dichloromethane (50 mL) solvent was added                                                                                                                                                                                    
Step 5d. & Step 5e. Dichloromethane (50 mL) was added twice time, then Step 5a, Step 5b. and Step 5c. 
repeated 
Step 6. Ethyl acetate (50 ml) solvent was added 
 
Step 6d. & Step 6e. Ethyl acetate (50 mL) was added twice then Step 6a., Step 6b. and Step 6c. repeated 
 
Step 6f. Aqueous ethanol fraction obtained  Step 6g. Ethyl acetate fraction obtained totaling (150 mL) 
   All obtained organic fractions of (n-hexane, dichloromethane and ethyl acetate) remaining water was removed using anhydrous NaSO4 then filtered with 
filter papers pore sized (10-12 µm), then with 0.45-μm syringe and 0.22 µm vacuum. Filter papers were washed using the same solvent (5mL) of fractions, then 
the filtrates were concentrated in rotary evaporator and dried in nitrogen stream gas flow completely.  
 
Step 7. The dry yield of fractions (g) weighted 
Hexane fraction    
 
Dichloromethane fraction Ethyl acetate   Aqueous ethanol fraction  
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3.7. Chemical characterization of the active fractions by GC-MS 
3.7.1. Derivatization of samples 
Gas chromatography (GC) is a widely known and used method, accepted by the Food and 
Agriculture Organization (FAO) for mixture analysis. It is reasonably fast, trustworthy, easy to 
master, with high detection sensitivity, separation efficiency, high selectivity, quick and low 
sample consuming. However, in GC analysis, compounds should be volatile or semi‐volatile i.e. 
have low boiling points, good thermal stability, and low molecular polarities
102
. In order to 
convert compounds with low volatility that are either undetectable or detected with a low 
sensitivity to those with ideal detection by GC analysis, chemical derivatization techniques can 
be applied. Derivatization is the chemical modification of compound to produce a new one with 
increased  volatility and separation properties that are more suitable for GC analysis
103,104
.  
Derivatization was done by adding methanol and acetyl chloride as a reagent. Dried fractions      
(5 mg) were treated with 1.5 mL of derivatization solution (methanol/acetyl chloride, 20:1, v/v), 
in 10 mL derivatization vessels and homogenized in the vortex (IKA, VWR, Leuven, Belgium) 
until complete dissolution for ∼2 min. Afterwards 1 mL of hexane was added, and the mixture 
was placed in a water bath for 1 hour at 70°C (Figure 11). After cooling in an ice bath for 15 
min, a mixture of ultra-pure water and n-hexane was added (1:4, v/v) and mixed on the vortex 
mixer at maximum speed in two cycles for 30 seconds at RT. In clean glass tube, the mixtures 
were centrifuged (2,000 rpm, 5 min, RT). The organic phase was collected, and the whole step 
was repeated one more time to make duplicate. Finally, remaining water was removed with an 
excess anhydrous sodium sulphate followed by filtration (syringe; 0.22 μM) into clean new 
tubes. Hexane was evaporated under a gentle nitrogen gas stream flow until complete dryness and 



















Figure 11: Some of the steps of the derivatization 
Fractions during the heat treatment, in a water bath of 70ºC (A), fractions after centrifugation (B), 
anhydrous sodium sulphate filtration through 0.22-µm PTFE filters (C), the ready of hexane fractions in 
the GC-MS analyzer (D). 
3.7.2. GC-MS analysis 
To discover bioactive compounds and apply it on biotechnological approaches, samples were 
analyzed on an Agilent GC-MS (Agilent Technologies 6890 Network GC System) coupled with 
MS detector (5973 Inert Mass Selective Detector) in a Bruker Scion 456/GC, Scion TQ MS 
coupled to a ZB-5MS capillary (30m × 0.25 μm i.d., 0.25 μm film thickness from Phenomenex). 
The column temperature program was set as follow: 
Initial oven temperature of 60°C for 1 min, increased to 120°C at the rate of 30°C/min and then 
increased to 250°C at 4°C/min  and then ramped to  300°C at a rate of  20°C/min, and held for 4 
min. A constant flow rate of 1 mL/min was used for the carrier gas (helium). Samples were 
injected at 300°C, operating in split less mode. Mass spectrometry (MS) was used to detect and 
quantify the separated compounds due to its more sensitive, faster, robust, high-resolution and 
accurate mass properties
102,103,104
. For the identification and quantification of bioactive 
compounds in fractions, the total ion mode was used.  
3.7.2.1. Expression of results 
 
In order to identify the compounds present in the active extract, Bruker MS workstation 
Software version 8.2.1 and MS Search version 2.0 was used. Peaks of eluting compounds were 
identified using mass spectra libraries of the National Institute Standard and Technology (NIST) 
applying a match quality of above 850 thresholds. Components‟ relative percentages were 
calculated based on GC peak areas with respect to total area of peaks. 




3.8. Statistical analysis 
All statistical analyses were performed using SPSS 26.0 statistical package for Windows (IBM 
SPSS Inc., Chicago, USA) software. All experiments were conducted three times. In each 
experiment six and eight replicates were performed in the assays of IC50 (color controls in 
duplicates) and preliminary screening respectively. Results were reported as mean ± standard 
error of mean (SEM). The data for all measures were tested for normality (Skewness-Kurtosis) 
and homogeneity (Levene‟s test) to see the quality of variance of homogeneity assumption; (% 
MCA) across  groups  of solvent-extracting and fractionating for the same species of algal and found to 
be normally distributed and homogeneous therefore, parametric statistical analysis was applied. 
The mean values of data were analyzed by analysis of variance (One-way ANOVA) for three 
groups; independent-samples t-Test for two groups was performed to identify the differences 
between factors. Statistical significance difference was determined at the 5% level (p<0.05). 
Once defined that differences existed among the means, post hoc pairwise multiple comparisons 
by Gabriel for unequal size (n) and Scheffe tests for equal n used. Prior to all statistical 
analyses, outliers were detected and removed using Boxplots showed the median, interquartile 
range, and outliers. The 50% chelating concentrations (IC50) were calculated by sigmoidal 
























4. RESULTS AND DISCUSSION 
4.1. Copper chelating activity (Cu
2+
CA) 
In the preliminary screening, the neuroprotective capacity of crude ethanol, ethyl acetate and 
water extracts from Haematococcus pluvialis (Hp), Isochrysis sp., Nannochloropsis sp., 
Phaeodactylum tricornutum (Pt), Porphyridium sp., Skeletonema costatum (Sc), Spirulina sp., 
Tetraselmis chui (Tc) and Tetraselmis sp. CTP4 (CTP4) was assessed in terms of chelating 






 at 10 mg/mL as shown in Table 9. EDTA was used as a 
positive control at 1 mg/mL and dimethyl sulfoxide (DMSO) was used as negative control. All 
extracts were dissolved in DMSO prior to the experiment. Results of the average metal 
chelating activity were expressed as percentage with respect to negative control. All extracts 
except H.  pluvialis, Spirulina sp., T. chui and Tetraselmis sp. CTP4 showed higher chelating 
copper as can be observed in Table 9 with values ranging from 62.5% to 87.1%. The best results 
were found to be in S. costatum extracts of ethanol, ethyl acetate and water (87.1%, 76.3% and 
74.2%) respectively. This could indicate that S. costatum extracts demonstrated higher capacity 
to chelate copper than others followed by ethanol extract of Isochrysis sp. (85.5%) and ethyl 























                  Table 9: Copper chelating activity (Cu
2+
CA, %) of extracts 
Species extracting-solvents Cu
2+
CA (10 mg/mL) 
H. pluvialis ethanol 51.9 ± 0.2
b
 
 ethyl acetate 59.5 ± 0.2
a
 
 water 20.3 ± 0.4
c
 
Isochrysis sp. ethanol 85.5 ± 0.1
a
 
 ethyl acetate 67.8 ± 0.5
c
 
 water 72.6 ± 0.5
b
 
Nannochloropsis sp. ethanol 43.5 ± 0.7
b
 
 ethyl acetate  3.61 ± 0.35
c
 
 water 72.3 ± 0.4
a
 
P. tricornutum ethanol 74.4 ± 0.6
a
 
         ethyl acetate 65.1 ± 0.9
b
 
 water 62.8 ± 1.6
b
 
Porphyridium sp. ethanol 62.5 ± 0.3
b
 
 ethyl acetate 82.4 ± 2.1
a
 
 water 52.5 ± 3.2
c
 
S. costatum ethanol 87.1 ± 0.2
a
 
 ethyl acetate         76.3 ± 0.1
b
 
  water    74.2 ± 0.5
c
 
Spirulina sp. ethanol    60.2 ± 1.7
a
 
 ethyl acetate    52.3 ± 0.1
b
 
 water    25.5 ± 1.2
c
 
T. chui ethanol    54.4 ± 6.5
a
 
 ethyl acetate    39.1 ± 5.6
b
 
 water    19.8 ± 4.8
c
 
Tetraselmis sp. CTP4 ethanol    47.7 ± 1.3
a
 
 ethyl acetate    44.6 ± 1.3
a
 




EDTA -    91.2 ± 0.3 
Results were expressed as mean ± SEM (standard error of mean) (n = 8). For each species, values 
labeled with different letters are significantly different (p < 0.05). 
*
EDTA = positive control, 1 mg/mL. 
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Next step in this study was to calculate the half-maximal chelating concentration (IC50, mg/mL). 
IC50 is a measure of the effectiveness of a compound to chelate 50% of copper that was found in 
the extract
85
. The most active extract is the one found with the lowest IC50 value as showed in 
Figure 12. We decided if the values are approximately less than 2 mg/mL to be considered as 































Figure 12: IC50 (dose response curve) of Cu
2+
CA of extracts 
Isp.EtOH = ethanol extract of Isochrysis sp.; Isp.EA = ethyl acetate extract of Isochrysis sp.; Isp.W = 
water extract of Isochrysis sp.; Nsp.W = water extract of Nannochloropsis sp.; PtEtOH = ethanol extract 
of P. tricornutum; PtEA = ethyl acetate extract of P. tricornutum; Psp.EtOH= ethanol extract of 
Porphyridium sp.; Psp.EA= ethyl acetate extract of Porphyridium sp.; ScEtOH = ethanol extract of S. 
costatum; ScEA = ethyl acetate extract of S. costatum; ScW = water extract of S. costatum. 








 Based on IC50 results, the most active extract with the lowest IC50 was identified in copper 
chelating activity, as can be seen in Table 10. The IC50 values with less than 2 mg/mL were the 
ones prepared from ethanol extract of Porphyridium sp., S. costatum and water extract of 
Isochrysis sp. valued with 1.44 mg/mL, 1.95 mg/mL and 1.84 mg/mL respectively.  
           Table 10: IC50 of Cu
2+
CA of extracts with respective 95% CI 
Species extracting-solvents                IC50  
mg/mL CI R² 
Isochrysis sp. ethanol 2.28 2.08 – 2.49 0.982 
 ethyl acetate  2.97 2.74 – 3.21 0.981 
 water 1.84 1.76 – 1.92 0.991 
Nannochloropsis sp. water 6.21 5.78 – 6.68 0.974 
P. tricornutum ethanol 3.58 3.41 – 3.78 0.995 
 ethyl acetate 7.37 6.77 – 8.05 0.954 
Porphyridium sp. ethanol 1.44 1.32 – 1.56 0.971 
 ethyl acetate 3.37 3.06 – 3.72 0.952 
S. costatum ethanol 1.95 1.77 – 2.14 0.962 
 ethyl acetate 4.87 4.21 – 5.68 0.881 
 water 4.34 4.05 – 4.65 0.963 
 
 
As chelating agent against copper, ethanol extract of the marine diatom Porphyridium sp. was 
identified as the most bioactive. The crude ethanol extract was fractionated into hexane, 
dichloromethane, ethyl acetate and aqueous ethanol. The polarity of the solvents used in the 
extraction process determines the composition and biological activity of a given extract
105
. 
Solvents of increasing polarity were used for the fractionation in order to separate and possibly 
isolate promising compounds that are responsible for neuroprotective compounds. Obtained 







CA at 10 mg/mL, 5 mg/mL and 1 mg/mL as a primary step to find an active 
fraction. Results shown in Table 11, hexane fractions from ethanol extracts of Porphyridium sp. 
and S. costatum were considerably the most active in chelating copper at 10 mg/mL, 5 mg/mL 
and 1 mg/mL.  
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 Table 11: Cu
2+
CA (%) of fractions  
Crude extracts fractionating-
solvents 

















 dichloromethane 61.1 ± 1.1
b
 44.3 ± 0.7
b
 12.9 ± 0.9
b
 
 ethyl acetate 
































 dichloromethane 61.4 ± 0.2
b
 42.1 ± 0.1
c
 19.4 ± 0.1
b
 
 ethyl acetate 

















EDTA ultra-pure water - - 93.2 ± 0.1 
Results were expressed as mean ± SEM (n = 8). Values labeled with different letters are significantly 
different at p < 0.05.
 *
EDTA = positive control. 
IC50 values were obtained from IC50 (95% CI dose response curve) in Figure 13 to see the 


















Figure 13: IC50 (dose response curve) of Cu
2+
CA of fractions 
Psp.Crude = crude extract of Porphyridium sp.; Psp.H = hexane fraction from Psp.Crude; Psp.DCM = 
dichloromethane fraction from Psp.Crude; Psp.EA = ethyl acetate fraction from Psp.Crude. 
ScCrude = crude extract of S. costatum; ScH = hexane fraction from ScCrude;  










 In Table 12 results suggest that, the IC50 values of hexane fractions of ethanol extract of 
Porphyridium sp. (0.461 mg/mL) and S. costatum (0.361 mg/mL) were lower than 
dichloromethane and ethyl acetate fractions and crude. This implies that the hexane fractions of 
ethanol extract of Porphyridium sp. and S. costatum were more effective as copper chelating 
therapeutic agents. Crude extracts were re-tested for their Cu
2+ 
chelation ability to make sure if 
the activity was maintained at 10 mg/mL, since the biomass was from different batch. As it can 
be seen clearly, the IC50 values were decreased in hexane fractions of Psp.EtOH (0.461 mg/mL) 
and ScEtOH (0.361 mg/mL) than in crude extract. However, in other fractions such as 
dichloromethane and ethyl acetate the IC50 values proved to be higher, meaning, chelating 
compounds have been concentrated in hexane fraction. 
         Table 12: IC50 of Cu
2+
CA of fractions with respective 95% CI 
Crude 
extracts 
fractionating-solvents 10 mg/mL IC50 
mg/mL CI R² 
Psp.EtOH crude extract 74.1 ± 0.6 2.72 2.48 – 2.99 0.961 
 hexane  0.461 0.362 – 0.561 0.864 
 dichloromethane  6.48 5.55 – 7.66 0.891 
 ethyl acetate  9.12 8.58 – 9.72 0.982 
ScEtOH crude extract 83.4 ± 0.4 2.41 2.16 – 2.66 0.954 
 hexane  0.361 0.322 – 0.393 0.963 
  dichloromethane  7.25 6.41 – 8.28 0.954 
  ethyl acetate  9.17 7.95 – 9.75 0.922 
          Results of crude extracts at 10 mg/mL expressed as mean ± SEM. 
As a result, those species can be used in the design of Alzheimer diseases chemotherapeutics, 
because it has been mentioned that copper is linked with neuron-related toxicity due to its 
redox-active nature (Cu/Cu
2+
). However, if it is in excess then it reacts with oxygen (O2) and 
generates reactive oxygen and nitrogen species (ROS and RNS). Those ROS are in the form of 
free radicals of cellular oxygen metabolism outcomes such as superoxide anion (O•2), hydroxyl 
radicals (OH•), nitric oxide (NO•) and non-free radicals. Those non-free radicals have ability in 
producing free radicals when they are exposed for chemical reaction, namely hydrogen peroxide 





after neuronal cell damage and death by binding with Cu
2+
 induced reactive oxygen species. 
Then they deposit as aggregation of proteins such as amyloid beta peptide in senile plaque in the 
AD patients‟ brain
107
. Thus, compounds that capture Cu
2+
 resulting in preventing the generation 
of reactive oxygen species, and attenuate abnormal copper-protein connection that lead to 
increased free-radical toxicity. Moreover, it can be promising pharmacological strategy to 
formulate copper induced neuronal disease mainly Alzheimer‟s. Different studies in the 
literature stated that algal fractions are rich in number of compounds
108,109
. Therefore, 
compounds that are present in the hexane fractions of Porphyridium sp. and S. costatum were 
selected to be chemically characterized and tentatively identified. As it was decided in section 
4.1, IC50 values higher than 2 mg/mL of fractions of dichloromethane, ethyl acetate fractions 
and crude were not promising for neuroprotective drug development and they were not 
subjected to characterization. 
4.2. Iron chelating activity (Fe
2+
CA) 
Ethanol, ethyl acetate and water extracts of those nine different species were evaluated for their 
iron chelating activity (Fe
2+
CA) at 10 mg/mL. EDTA (1 mg/mL) was used as positive control 
and DMSO was used as negative control. In the first phase screening, Fe
2+ 
chelating activity 
varied greatly among extracts and/or species. Table 13 shows Fe
2+
chelating activity found in 
water extracts ranging from 34.7% to 96.6% in Porphyridium sp. and Tetraselmis sp. CTP4, in 
ethanol extracts from 3.23% to 75.1% in Tetraselmis sp. CTP4 and Isochrysis sp. respectively. 
The maximum Fe
2+
 chelating capacity was observed in the water extracts of Tetraselmis sp. 
CTP4 (96.6%) and Isochrysis sp. (79.1%). It has been reported that results obtained with T. chui 
and Isochrysis sp. by Custódio et al. (2012, 2014) exhibited iron chelation capacity that contain 
antioxidants with potential application in the treatment of oxidative stress related diseases like 
AD
13,61
. Nannochloropsis sp. also had high chelating ability (83.2%). In the literature Goh et al. 
(2010) has mentioned that methanol extract of Nannochloropsis sp. had the most chelating 
ability towards iron ion
110
. Water extract of P. tricornutum (75.2%) and ethanol extract of 
Isochrysis sp. (75.1%) and Porphyridium sp. (71.7%) revealed considerable iron chelation 
effect. In similar finding of Kean et al. (2015) capturing ability has been identified in P. 
tricornutum
111
. It has been stated that, iron accumulation and oxidative damage are associated 
with neurological disorders.  
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                          Table 13: Iron chelating activity (Fe
2+
CA, %) of extracts  
Species extracting-solvents 10 mg/mL 
H.  pluvialis ethanol 6.61 ± 0.73
a
 
 ethyl acetate 4.71 ± 0.48
b
 
 water 1.92 ± 1.21
c
 
Isochrysis sp. ethanol 75.1 ± 0.1
a
 
 ethyl acetate 42.7 ± 1.1
b
 
 water 79.1 ± 1.9
a
 
Nannochloropsis sp. ethanol 19.7 ± 0.5
b
 
 ethyl acetate 4.11 ± 0.12
c
 
 water 83.2 ± 0.1
a
 
P. tricornutum ethanol 58.8 ± 1.4
b
 
 ethyl acetate 11.8 ± 0.1
c
 
 water 75.2 ± 0.9
a
 
Porphyridium sp. ethanol 71.7 ± 0.1
a
 
 ethyl acetate 47.6 ± 0.5
b
 
 water 34.7 ± 0.2
c
 
S. costatum ethanol 53.4 ± 0.1
b
 
 ethyl acetate 42.4 ± 0.6
c
 
 water 63.8 ± 0.9
a
 
Spirulina sp. ethanol 6.04 ± 0.62
a
 
 ethyl acetate 4.46 ± 0.27
b
 
 water 1.71 ± 0.21
c
 
T. chui ethanol 16.6 ± 0.7
a
 
 ethyl acetate 15.8 ± 0.3
a
 
 water 4.91 ± 0.23
b
 
Tetraselmis sp. CTP4 ethanol 3.23 ± 0.15
c
 
 ethyl acetate 33.2 ± 0.4
b
 




EDTA ultra-pure water 96.1 ± 0.2 
Results were expressed as mean ± SEM. Values labeled with different letters are significantly different 
at p < 0.05. *EDTA = Positive control, (1 mg/mL). 
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 is a main reason for increase in oxidative 
stress of lipid peroxidation and lead to oxidative damage of senile plaques
108
. It is a right 
approach to chelate Fe
2+
 and compounds that have ability to scavenge the free Fe
2+
 cations 
found in the brain to form a non-toxic metal complex
108
. 
The following step was to calculate the (IC50, mg/mL) of extracts that showed Fe
2+
CA > 60%. 
Those were water extracts of Tetraselmis sp. CTP4, Isochrysis sp., Nannochloropsis sp. and P. 
tricornutum and ethanol extracts of Isochrysis sp., Porphyridium sp. and S. costatum. The most 
active extracts having higher capacity to chelate Fe
2+
 ions were the ones found with the lowest 
IC50 value as shown in Figure 14 and Table 14 were ethanol extracts of Porphyridium sp. (0.942 

























Figure 14: IC50 (dose response curve) of Fe
2+
CA of extracts 
PtW = water extract of P. tricornutum; water extract of Tetraselmis sp. CTP4 
Error bars show the standard deviation of six replicates. 
 
   




Table 14: IC50 of Fe
2+




mg/mL CI R² 
Tetraselmis sp. CTP4 water 4.23 4.17 - 4.30 0.992 
Isochrysis sp. ethanol 2.28 2.11 - 2.46 0.981 
  water 4.43 4.11 - 4.79 0.973 
Nannochloropsis sp. water 3.07 2.74 - 3.44 0.943 
P. tricornutum  water 5.59 5.25 - 5.96 0.982 
Porphyridium sp. ethanol 0.942 0.812 - 1.08 0.921 
S. costatum ethanol 0.883 0.771 - 0.992 0.954 
 
 
Table 15 indicates that hexane fractions of ethanol extract of Porphyridium sp. and S. costatum 
were pointedly higher at p<0.05 in chelating iron at 10 mg/mL, 5 mg/mL, 1 mg/mL of 85.2%, 
78.5% and 60.9%, and 97.9%, 97.3% and 88.7% respectively than fractions obtained from 
dichloromethane and ethyl acetate .  
 
     Table 15: Fe
2+
CA (%) of fractions 
Crude extracts fractionating- solvents 10 mg/mL 5 mg/mL 1 mg/mL 
Psp.EtOH crude extract 77.4 ± 0.2 75.1 ± 0.7 61.6 ± 0.3 
 hexane 85.2 ± 0.4
a
 78.5 ± 0.6
a
 60.9 ± 0.2
a
 
 dichloromethane 61.1 ± 1.1
b
 44.3 ± 0.7
b
 12.8 ± 0.9
b
 

















ScEtOH crude extract 83.5 ± 1.6 62.3 ± 1.3 22.1 ± 0.1 
 hexane 97.9 ± 0.3
a
 97.3 ± 0.1
a
 88.7 ± 0.2
a
 
 dichloromethane 61.4 ± 0.2
b
 42.1 ± 0.1
c
 19.4 ± 0.2
b
 

















*EDTA ultra-pure water - - 95.3 ± 0.1 




Results in Figure 15 and Table 16 suggest that the highest Fe
2+
CA with low IC50 value were 
seen in hexane fractions from ethanol extracts of Porphyridium sp. and S. costatum of (0.292 
mg/mL) and (0.263 mg/mL). Interestingly, our result advocates that those hexane fractions were 


































Figure 15: IC50 (dose response curve) of Fe
2+
CA of fractions  
 
Iron has a significant catalyzing effect in Fenton reaction in making reactive oxygen species by 
enhancing oxidative stress leading to neuron-related diseases. Even though, Fe
2+
 is an important 
cation for several enzymes, accumulation of Fe
2+
 has been implicated in several pathological 
conditions of metabolic processes like protein aggregation and oxidative stress
112
. It has been 
reported that, it leads to abnormal combination of protein aggregates in neuron and amyloid 
   




plaques in the brain‟s mitochondria. Hydroxyl radical is very reactive, unstable, forms those 
modified aggregates, which are able to damage macromolecules of mitochondria and other 
cellular structures. Damaged mitochondria are sources of intracellular free radicals. The 
interactions of generated ROS and redox-active Fe
2+
 contribute to oxidative stress damage in 
AD patient‟s brain
108,112
. Thus, compounds with the capacity to chelate excess redox-active 




, prevent or inactive uncontrolled generation of redox-metal 
induced reactive oxygen species complexes, inhibit oxidative stress in the Alzheimer‟s patient 
brain
112
. Those can contribute to convincingly direct design of drugs for treatment of neuron-
related diseases
113
.   
Table 16 presents the IC50 values (mg/mL) of fractions of hexane and ethyl acetate from 
ethanolic extract of Porphyridium sp. and hexane, dichloromethane and ethyl acetate fractions 
from ethanolic extract of S. costatum. 
    Table 16: IC50 of Fe
2+
CA of fraction with respective 95% CI 
Crude extracts 
 
fractionating-solvents 10 (mg/mL) IC50 
mg/mL   CI R² 
Psp.EtOH crude extract 77.4 ± 0.2 0.522 0.471 – 0.572 0.972 
 hexane  0.292 0.262 – 0.332 0.971 
 ethyl acetate  4.22 3.74 – 4.78 0.933 
ScEtOH crude extract 83.5 ± 1.6 0.551 0.492 –  0.601 0.953 
 hexane  0.263 0.252 –  0.274 0.994 
 dichloromethane  4.25 3.88 –  4.66 0.961 
 ethyl acetate  2.71 2.27 – 3.24 0.864 
 





) chelating compounds.  
4.3. Calcium chelating activity (Ca
2+
CA)  
Apart from redox-active metal ions, in human brain, calcium is a divalent cation that regularly 
originates from intracellular stores in the endoplasmic reticulum to control many neuronal 
functions. Calcium (Ca
2+
) has a great role for the interfacing between electrical and signal world 
in neuronal processes
114





 dependent signaling, learning, memory and neuronal survival purposes. Calcium overload 
is able to cause damage to cell structures, loss of synapses and neurons cell, decline of cognitive 
capacity, and emotional disturbances. Alzheimer‟s disease is the most common Ca
2+
 induced 
neurodegenerative disease. Patients show loss of cognitive abilities due to short and long term 
neurodegeneration or cell death 
114,115
. In order to sustain the neuronal process and integrity, the 
flow of Ca
2+
 within homo-cellular and hetero-cellular across the plasma and mitochondria 
membranes between intracellular organelles need to be controlled. Naturally it can be controlled 
by ion channels, Ca
2+
 binding proteins, ion exchangers, and voltage-operated channels (that 
release neurotransmitters at synaptic junctions)
116
. However, interaction of Ca
2+
 with proteins 
and reactive oxygen signaling species can be useful and harmful. Unregulated flow of Ca
2+
 can 
lead to impaired synaptic plasticity, and disassembly of synaptic connections due to proteins 
and neuronal damage
115
. Death of cells in the brain causes oxidative stress that leads to 
neurodegenerative diseases such as: Alzheimer‟s and brain inflammation.  
Compounds that chelate calcium might be helpful. Indeed, they stabilize neuronal Ca
2+
 
homeostasis, may retard cell degeneration in acute and chronic neurodegenerative conditions, 
and support neuronal survival. If immune-compounds were able to remove amyloid beta protein 
from the brain, immunization would be expected to prevent or reverse also the amyloid beta 




. Similarly, new chelating compounds with 
potential to get ride of excess flow of calcium in the brain are important ways to develop a 




.   
In present study, ethanol, ethyl acetate and water extracts of all species were tested for Ca
2+
CA 
at 10 mg/mL. EGTA (1 mg/mL) and DMSO were used as positive and negative control 
respectively. The results show that only ethanol extracts from Porphyridium sp. (75.8%) and S. 
costatum (87.8%) and ethyl acetate extract of S. costatum (86.7%) and Porphyridium sp. 
(67.3%) had highest Ca
2+ 
chelating ability presented in Table 17, however, extracts of ethanol 
and ethyl acetate of S. costatum are not significantly different at p<0.05 level. So that, ethanol 
extract of S. costatum is considered as the best candidate for a source of compounds with 




. Therefore, ethanol and ethyl acetate 







                Table 17: Calcium chelating activity (Ca
2+
CA, %) of extracts 
Species extracting-solvents 10 mg/mL 
H. pluvialis ethanol 0.702 ± 0.122
c
 
  ethyl acetate 2.41 ± 0.76
b
 
  water 8.12 ± 0.76
a
 
Isochrysis sp. ethanol 52.8 ± 0.7
a
 
  ethyl acetate 38.1 ± 0.2
b
 
  water 6.67 ± 0.46
c
 
Nannochloropsis sp. ethanol 15.5 ± 0.6
a
 
  ethyl acetate 7.98 ± 0.15
b
 
  water 13.2 ± 1.5
a
 
P. tricornutum ethanol 35.2 ± 1.1
b
 
  ethyl acetate 48.1 ± 0.5
a
 
  water 47.4 ± 0.5
a
 
Porphyridium sp. ethanol 75.8 ± 0.1
a
 
  ethyl acetate 67.3 ± 1.3
b
 
  water 28.6 ± 0.1
c
 
S. costatum ethanol 87.8 ± 1.7
a
 
  ethyl acetate 86.7 ± 1.6
a
 
  water 24.3 ± 0.8
b
 
Spirulina sp. ethanol 48.8 ± 0.4
a
 
  ethyl acetate 19.4 ± 0.3
b
 
  water 7.12 ± 0.31
c
 
T. chui ethanol 48.9 ± 0.5
b
 
  ethyl acetate 57.2 ± 2.1
a
 
  water 23.1 ± 2.2
c
 
Tetraselmis sp.CTP4 ethanol 54.7 ± 1.1
a
 
  ethyl acetate 12.3 ± 0.3
b
 




EGTA - 85.9 ± 0.5 
Results were expressed as mean ± SEM (n = 8). Values labeled with different letters are significantly 
different (p < 0.05). 
*
EGTA = Positive control, 1 mg/mL. 
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Interestingly, results shown in Figure 16, ethanol extracts of Porphyridium sp. and S. costatum 
displayed the most calcium chelating activity. Bioactive compounds of Porphyridium sp. and S. 
costatum could chelate 50% of free calcium ions that are found in both species at low 
concentration of 0.832 mg/mL and 1.02 mg/mL respectively (Table 18). Therefore, both 
extracts proceeded to fractionation stage to concentrate compounds that are responsible in 
chelating of Ca
2+





















Figure 16: IC50 (dose response curve) of Ca
2+
CA of extracts  
 
     
                Table 18: IC50 of Ca
2+
CA of extracts with respective 95% CI 
Species 
 
extracting-solvents IC50  
mg/mL CI R² 
Porphyridium sp. ethanol 0.832 0.762 - 0.911 0.972 
 ethyl acetate 2.41 2.26 - 2.55 0.981 
S. costatum ethanol 1.02 0.883 - 1.19 0.923 








Ethanol extracts of Porphyridium sp. and S. costatum were subjected to fractionation using 
organic solvent of hexane, dichloromethane and ethyl acetate. We obtained fractions                
re-evaluated for calcium chelating activity at 10 mg/mL, 5mg/mL and 1 mg/mL as initial 
analysis to test their activity. According to results that are visualized in Table 19 the hexane 
fraction of ethanol extract of Porphyridium sp. (95.4%, 93.8% and 71.5%) and S. costatum 
(97.1%, 96.2% and 88.5%) showed maximum activity among others at 10 mg/mL, 5mg/mL and 
1 mg/mL respectively. The next step was to test the hexane fractions 50% chelating 
concentrations (IC50). 
 
  Table 19: Ca
2+
CA (%) of fractions  
Crude 
extracts 

















 dichloromethane 52.5 ± 0.1
d
 47.6 ± 0.6
c
 37.8 ± 0.1
b
 

































 dichloromethane 80.1 ± 0.6
b
 72.2 ± 0.6
b
 34.5 ± 0.3
c
 


















EGTA ultra-pure water - - 91.1 ± 0.1 
Psp.EtOH = ethanol extract from Porphyridium sp.; ScEtOH = ethanol extract from Skeletonema 
costatum. 
*
EGTA = positive control. 
 
As clearly shown in the Figure 17 that confirming hexane fractions of Porphyridium sp. and S. 
costatum exhibited 50% chelation at lower concentration when compare to the others with the 





























Figure 17: IC50 (dose response curve) of Ca
2+
CA of fractions 
 
 
        Table 20: IC50 of Ca
2+








mg/mL CI R² 
Psp.EtOH crude extract 80.1 ± 0.3 1.06 0.88 – 1.27 0.891 
 hexane  0.451 0.432 –  0.471 0.992 
 dichloromethane  4.43 3.85 – 5.12 0.901 
 ethyl acetate  3.03 2.75 – 3.31 0.963 
ScEtOH crude extract 88.6 ± 0.7 1.36 1.26 – 1.47 0.972 
 hexane  0.181 0.173 – 0.192 0.994 
 dichloromethane  1.66 1.54 – 1.77 0.981 
 ethyl acetate  1.35 1.24 – 1.45 0.984 
 







Clearly as can be noticed in Table 11, Table 15 and Table 19, hexane fraction of ethanol extract 
from Porphyridium sp. and S. costatum presented high chelating activity at 10 mg/mL,              
5 mg/mL and 1 mg/mL for copper, iron and calcium. The values for Cu
2+
CA are 81.2%, 70.5% 
and 64.4%, and with an IC50 value of 0.461 mg/mL for Porphyridium sp., and 92.6%, 80.4%, 
and 64.1%, and with an IC50 value of 0.361 mg/mL for S. costatum respectively. Similarly, for 
Fe
2+
CA, 85.2%, 78.5% and 60.9% with an IC50 of 0.292 mg/mL, and 97.9%, 97.3% and 88.7% 
and with an IC50 value of 0.263 mg/mL for Porphyridium sp. and S. costatum respectively.  
In the case of calcium chelating activity of hexane fraction from ethanol extract of 
Porphyridium sp. and S. costatum also contributed in slight proximity to each other at 10 
mg/mL, 5 mg/mL and 1 mg/mL with values of 95.4%, 93.8% and 71.5% with an IC50 = 0.451, 
and 97.1%, 96.2% and 88.5% with IC50 value of 0.181 mg/mL respectively. This explains that 
compounds that are responsible for the activity are from the same polarity family, since it is 
known that the activity of target compounds and the solvent depends on polarity as it dictates 
reciprocal solubility, which means non-polar compounds are better-extracted using non-polar 
solvents. Hexane (a non-polar solvent) has been used widely all over the world as a solvent for 
extracting saturated, mono and poly unsaturated fatty acid or lipids
91
. Since, microalgae are rich 
in fatty acids, carotenoids, sterols, vitamins, and lipids, different methods have been applied to 
extract those compounds
91
. Therefore, both extracts are expected to have metabolites of fatty 
acid, sterols, vitamins, and lipids groups. 
In general, at 10 mg/mL, extracts with greater than 50% MCA are considered as active in 
chelating metals. Taking this in consideration, ethanol, ethyl acetate and water extract of nine 
species were significantly varied among each other. As general comparison, extracts showed 










 chelating activity of extracts 
were moderate; the ethanol and ethyl acetate extract had higher MCA than water except Fe
2+
CA 
water extract of Tetraselmis sp. CTP4 (96.6%), Isochrysis sp. (79.1%), Nannochloropsis sp. 
(83.2%), P. tricornutum (75.2 ), S. costatum (63.8%); Cu
2+
CA of water extract of Isochrysis sp. 
(72.6%), Nannochloropsis sp. (72.3%), P. tricornutum (62.8%), Porphyridium sp. (52.5%) and 
S. costatum (74.2%) and Ca
2+
CA of water extract of Tetraselmis sp. CTP4 (58.6%) were 
significant.  
The differences of activity within the same species can be due to the difference in polarity of 
extracting-solvents type, extract preparation methods, state of chemicals and concentrations, 
environment and algal content of bio-active constituents. Those factors can potentially affect the 
60 
 
extracted metal chelating compounds
105,117,118







CA of hexane fractions from ethanolic extract of Porphyridium sp. and S. costatum 
were reported for the first time. In addition, the chelation activity of Porphyridium sp. and S. 
costatum were not showed as metal chelating selecting, meaning that both presented copper, 
iron and calcium chelation activity. Which was the claim of synthetic chelator such as  EDTA 
and EGTA, that chelate all metals found in the brain, that cause deficiency of useful bio-metals 
in the brain
44
. Algal extracts from different batches were proved that the percentage of metal 
chelating activity at the same concentration were approximately steady. It has been reported that 
microalgae are naturally capable of adapting to different seasons and conditions (temperature, 
light and pH)
119
. Despite the fact that, the percentage of metal chelating activity of the same 
species has shown differences amongst the batches, which are common because the cultivating 
conditions, methods in extraction and fractionation procedures can influence compounds 
concentration and biochemical composition of the microalgae
105
.  
Organic solvents such as hexane, dichloromethane, ethyl acetate were used to accumulate 
(concentrate) the compounds in their polarity difference. Solvents with polarity difference have 
a great factor to extract drug lead compounds from algal extract. Those fractionating-organic 
solvents were chosen with their polarity difference in order to make them suitable for research 
purposes including chemical characterization. Hexane is allowed by the Food and Drugs 
Administration (FDA) to be used in food and analytical laboratories for scientific 
investigation
67
. Both species extracts of non-polar (hexane) fractions possessed an excellent 






. That are pointing to a possible 
beneficial role as cation chelators having class of fatty acids, vitamins, sterols and others
61
. 
Thus, marine microalgae have proved that, as a potential source of compounds with 













4.4. Chemical Characterization 
In the past decades, marine microalgae gained popularity due to previously discovered novel 
and unique bio-active compounds
120
. In the result and discussion section, the hexane fractions 
from ethanol extract of algal species of Porphyridium sp. and S. costatum were concluded as the 
most promising in terms of copper, iron and calcium chelating activity.  
In this section, those fractions were analyzed by using GC-MS in order to potentially identify 
their main neuron-protective compounds. GC-MS is a technique usually employed for 
separation, identification and quantification of volatile and semi-volatile compounds
118
.  
Algal species are composed of non-volatile compounds such as fatty acids and their various 
substituted forms. Derivatization was done to convert into derivatives suitable for GC. Treating 
the sample with methanol and acetyl chloride using derivatization (whose details were described 
in Section 3.7.1) were the main tasks. Then, GC-MS separated compounds of hexane fraction 
from ethanol extract of Porphyridium sp. and S. costatum, and tentatively identified compounds 
using GC-MS presented in (Table 21) and (Table 22) respectively. The peaks were identified by 
comparing linear retention times (minute), total area of the compounds, and their relative 
contribution to the total composition (percentage of total area). Those results matched with 
spectrum fragmentation pattern of the mass spectra in NIST library
121
.  
While interpreting the GC-MS result, the functional group has been modified from methylated 
ester (RCOO-CH3) or methoxy (RO-CH3) to carboxylic acid (RCOO-H) or alcoholic functional 
group (RO-H) respectively. The mechanism performed by substituting hydrogen in the place of 
methyl from their methyl attached portion. This process has advantages in the creation of 
volatile compounds, however, it might lead to confusion in distinguishing between the presence 




The GC-MS analysis identified a total of 44 and 42 peaks from Porphyridium sp. and S. 








Table 21: Identified compounds present in hexane fraction of Psp.EtOH using GC-MS 
Retention  
time (min) 




23.4 Hexadecanoic acid SFA 27.8 
30.9 5,8,11,14-Eicosatetraenoic acid PUFA 13.4 
31.1 5,8,11,14,17- Eicosapentaenoic acid PUFA 7.49 
27.2 9,12-Octadecadienoic acid PUFA 7.22 
22.6 7-Hexadecenoic acid MUFA 3.48 
27.4 11-Octadecenoic acid MUFA 2.05 
31.5 11,14-Eicosadienoic acid PUFA 1.75 
27.2 9-Octadecenoic acid MUFA 0.881 
25.7 Tetrahydropyranyl ether of citronellol ether 0.681 
31.3 cis-5,8,11,14,17- Eicosapentaenoic acid PUFA 0.401 
22.2 9,12,15-Octadecatrienoic acid PUFA 0.359 
26.6 γ-linolenic acid PUFA 0.294 
31.4 4,7,10,13,16,19-Docosahexaenoic acid PUFA 0.205 
31.6 9-Eicosenoic acid MUFA 0.201 
34.7 6,9,12,15-Docosatetraenoic acid. PUFA 0.159 
23.6 Pregna-5,9(11)-dien-20-ol-3-one ethylene ketal sterol 0.155 
34.4 4,7,10,13,16-Docosapentaenoic acid PUFA 0.123 









Total   95.7 
 
According to GC-MS results three main chemical functional groups from Porphyridium sp. 
(Table 21) were identified such as: 
  Fatty acids  
  Two saturated fatty acids (SFA)  
  Five monounsaturated fatty acids (MUFA)   
  Ten polyunsaturated fatty acids (PUFA) 
  One sterol 
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  One ether  
  Unidentified compounds  
Table 22: Identified compounds present in hexane fraction of ScEtOH by (GC-MS) 
Retention  
time (min) 
compounds chemical classes total 
 area (%) 
18.6 Tetradecanoic acid SFA 31.7 
23.2 9-Hexadecenoic acid MUFA 21.9 
23.7 Hexadecanoic acid SFA 12.1 
14.9 1,1-Dodecanediol alcohol 3.48 
22.3 9,12,15-Octadecatrienoic acid PUFA 1.83 
41.7 Cholesterol sterol 1.51 
30.8 5,8,11,14,17-Eicosapentaenoic acid PUFA 1.35 
27.4 trans 13-Octadecenoic acid MUFA 1.21 
20.1 3,7,11,15-Tetramethyl-2-hexadecen-1-ol alcohol 0.991 
24.7 9,12-Octadienoic acid PUFA 0.937 
27.3 9-Octadecenoic acid MUFA 0.924 
38.1 Tetracosanoic acid SFA 0.827 
27.9 Octadecanoic acid SFA 0.686 
24.2 3,3,6-Trimethyl-1,5-heptadien-4-ol alcohol 0.683 
30.9 9,10-Dihydroxy octadecanoic acid PUFA 0.348 
26.8 8,11,14,17-Eicosatetraenoic acid PUFA 0.346 
27.5 Phytol alcohol 0.329 
23.3 7-Hexadecenoic acid MUFA 0.223 
24.1 7,10-Hexadecadienoic acid PUFA 0.159 
37.9 15-Tetracosenoic acid MUFA 0.142 
36.1 Docosanoic acid SFA 0.118 
37.8 Gamma-sitosterol sterol 0.102 
- Unidentified compounds -    10.2 




Analyzed three chemical functions from S. costatum were as follow: 
  Fatty acids  
  Five saturated fatty acids (SFA) 
  Five monounsaturated fatty acids (MUFA)  
  Six polyunsaturated fatty acids (PUFA) 
  Four long-chain alcohols 
  Two sterols 
  Unidentified compounds 
Among tentatively identified compounds present in hexane fractions of Psp.EtOH and ScEtOH 
visibly SFA, PUFA, alcoholic long-chain alcohols and MUFA were dominant in number. Those 
most dominant compounds were reported as bioactive compounds with biomedical activity in 
the pharmacological fields to treat diseases like cancer, oxidative stress neuron-related
122
, viral, 
fungal, bacterial, diabetic, hypercholesterolemia and inflammation
123
. Similar chemical groups 
were previously identified from hexane extract of algal species in which polyunsaturated fatty 
acids
124
 and steroids were the most abundant compounds
13
, as a promising cation chelating 
agent and antioxidant. Therefore, compounds found in Porphyridium sp. and S. costatum can 
have neuron-protective ability. Compounds such as hexadecanoic acid (27.8%); 5,8,11,14-
eicosatetraenoic acid (13.4%); 5,8,11,14,17-eicosapentaenoic acid (7.49%) and 9,12-
octadecadienoic acid (7.22%) were the most abundant found in Porphyridium sp., and 
tetradecanoic acid (31.7%); followed by 9-hexadecenoic acid (21.9%), hexadecanoic acid 
(12.1%) and 1,1-dodecanediol were the leading in S. costatum. 
It has been reported that hexadecanoic acid was identified from non-algal natural extracts of 




 and from Spongia officinalis and 
Cystoserio compressa as antimicrobial agent
125
. Previously, hexadecanoic acid has been 
mentioned as most abundant in Phaeodactylum species
126
. As can be observed in Table 21, the 
most abundant peak identified by GC-MS was hexadecanoic acid with 27.8% of total peak area 
in which it has been described as antioxidant from algal Sun clorella
106
 and also from the Red 
Algae Laurencia brandenii. Hexadecanoic acid was recorded as cytotoxic agents
123,127
. Thus 
recognizes that Porphyridium sp. could be significant source of bioactive compounds with 
neuroprotective capacity as well. 
Apart from a high content of fatty acids, sterols were commonly found in algal species such as 
Nannochloropsis sp., Tetraselmis sp., Chlorella vulgaris and Cyanophora paradoxa. Naturally 
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occurring cholesterol-like triterpenes in plants and animals contribute to the regulation of 
membrane fluidity and permeability and form part of the structural components of cell 
membrane in different organisms. Due to their biological activities, may act as ROS 
scavengers
13
, with antioxidant, anti-inflammatory and anti-hypercholesterolemic effects. Sterols 
improve neurological functions by preventing central nervous system from neuronal 
inflammation and by protecting from free radicals, β-amyloid-induced neurotoxicity leading to 
improved cognition in AD patients
13,128
. In this study, we have identified two sterols from 
Porphyridium sp. Pregna-5,9 (11)-dien-20-ol-3-one ethylene ketal( ) with 0.155% at retention 
time of 23.6 min (Table 21) and from S. costatum in the form of cholesterol with 1.51% at 
retention time of 41.7 min (Table 22). In this consideration, both sterols could provide a 
valuable source for neuroprotective capacity.  
It is obviously known that pharmaceutical industries have been desperately searching for a 
novel compounds that have not been previously identified. In this study out of 44 and 42 
detected peaks, 19 and 22 were successfully identified using NIST library, with 95.7% and 
92.1% of total peak area from hexane fraction of ethanol extract of Porphyridium sp. and S. 
costatum respectively. However, among unrevealed compounds, the largest peaks presented by 
Porphyridium sp. were as unidentified compounds (28.9%) of total peak area. Unidentified 
compounds were also presented in S. costatum at 10.2% of total area. Therefore, the majority of 
volatile or semi-volatile compounds present in the hexane fractions were successfully identified. 
At this stage of study, it is difficult to pinpoint one specific compound that is responsible for 
cation chelator as a neuroprotective compound. However, the results shows that the most 
abundant compounds of saturated fatty acid of hexadecanoic acid, polyunsaturated fatty acid of 
5,8,11,14-eicosatetraenoic acid and 5,8,11,14,17-eicosapentaenoic acid from Porphyridium sp. 
and mono unsaturated fatty acid of 7-hexadecenoic acid from, and saturated fatty acid of 
tetradecanoic acid, mono unsaturated fatty acid of 9-hexadecenoic acid and alcohol of 1,1-
dodecanediol form S. costatum might act as cation chelating compounds, possessing 
neuroprotective activity. 
Among identified compounds, long-chain fatty acids are the most abundant, polyunsaturated 
fatty acids were clearly seen as the most dominant compounds in the hexane fraction from 
ethanolic extract of Porphyridium sp. and S. costatum. It has been well explained that hexane 
extracts of microalgae are a significant source of polyunsaturated fatty acids such as 
5,8,11,14,17-eicosapentaenoic acid which was identified as a dominant compound from hexane 
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extract of  T. chui
13
. In this study, results show that Porphyridium sp. and S. costatum were 
reach in polyunsaturated fatty acids of 5,8,11,14-eicosatetraenoic acid and 5,8,11,14,17-
eicosapentaenoic acid, and 5,8,11,14,17-eicosapentaenoic acid respectively. Porphyridium sp. 
and S. costatum exhibited a higher ability to chelate copper, iron and calcium in both polar and 
non-polar fractions. Genuinely it implies that compounds who are responsible to chelate the 







compounds found in the slightly polar fractions of dichloromethane (PI = 3.10) and ethyl 
acetate (PI = 4.40) performed less than in non-polar solvent of hexane (PI = 0.10) since the 











The structure, conjugate bond, electron donor and/or acceptor sites of these compounds (or 
functional groups) are the main participants in the chelation mechanism
13
.   
The term chelator is derived from Greek word “chele” which means “crab‟s claw” or holding 
with a strong grip. The chelation complex is formed by a ligand or molecule containing at least 
two donor groups (or coordination numbers) connected to their substrates or ions to bind metal 
ions and form stable complexes
52
. Chelating agents are organic or inorganic compounds capable 
of binding metal ions. Chelating atoms can form either two covalent linkages the term bidentate 
refers to two donor groups or two coordinate linkages and so, bidentate chelators, tridentate 
chelators are linked to three coordinates or covalent linkages
37
 as chelating rings and so on. 
Other types of chelating ligands are possible, like EDTA, which is a hexadentate ligand. Some 




Chelating agents form covalent linkages or coordinate and multi dentate ligands with atoms 
attached to the metal. Mainly atoms like S, N and O function as ligand atoms in the form of 
chemical groups like –SH, –S-S, –NH2, =NH, –OH, –OPO3H, or >C=O
37
. The following figure 








Figure 18: Formation of metal ligand complexes due to chelators 
M implies metals to be chelate by means of dentate (D) or chelating site. 
Compounds that were identified in this study, unsaturated fatty acids especially polyunsaturated 
fatty acids might be responsible for the chelation character. Since, they have double bonds
91
, the 
delocalization of π-electrons enhances the lipophilicity (ability to dissolve in oils, fats, lipids, 
and non-polar solvents) of the complexes, ending up to block the metal binding sites. Chelate 
formation through ring size, number of aromatics and heterocyclic rings (rings, which contain 
sulfur, nitrogen, and/or oxygen) are responsible for the metal chelating activity and their metal 
complexes formation
129
. Polyunsaturated fatty acids contain C=O at the active chelating site, 
since it contains π-electrons and also two pair donating electrons in the oxygen atoms that 
makes the compound able to chelate metal ions
37
.  
Compounds that have been identified in this study such as 9,12-octadecadienoic acid (Z,Z) (left) 
at retention time of 27.2 min and 5,8,11,14,17-eicosapentaenoic acid (right) at retention time of 
31.1 min are good examples having poly dentate groups due to C=O and π-electrons as a metal 




     
         9,12-Octadecadienoic acid (Z,Z)                    5,8,11,14,17-Eicosapentaenoic acid 
Figure 19: Examples of chelating compounds having poly-dentate site 
Compound 9,12-otadecadienoic acid (Z,Z) was from hexane fraction of Psp.EtOH and 5,8,11,14,17- 
eicosapentaenoic acid was from hexane fraction of ScEtOH. 
 
In the compound 9,12-octadecadienoic acid (Z,Z) the 4 chelating sites are the following: two 
oxygen atoms that are bonded at the first carbon atom (each oxygen atom contains a pair of 







 that are found in the brain) bonds. Equally, 5,8,11,14,17- eicosapentaenoic 
acid, has 7 chelating sites: two oxygen atoms and π-electrons in carbon atom of 5,8,11,14 and 






 ions of overload in the Alzheimer patients 
brain. 
Natural chelators characterized by same distribution as the metal with greater affinity having 
low toxicity able to penetrate via cell membranes, rapidly soluble in water and ultimately 
eliminate toxic metal by forming stable and non-toxic complexes. They regularly rescue the 
cells by shielding biological targets from further damage, loss and death
37
.  
However, most of the compounds that were identified in this study could be metal chelators; are 
non-polar and insoluble in water. By using metal chelating agents, it have been possible to 
reduce the cation concentrations in the brains of patients with AD, leading to a small, but 
significant improvement in cognitive function
130
. 
In order to investigate the exact compound, further studies are very important and needed. We 
recommend that hexane fraction of both species Porphyridium sp. and S. costatum should be 
re-fractionated again, separate fatty acid mixture into one fraction rich in saturated fatty acids 
and the other rich in unsaturated acids. These obtained sub-fractions should be re-tested for their 
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). Through this the number of compounds can 
be reduced and it becomes easy to understand the mechanism to target specific compounds with 
neuroprotective capacity.  
In this study only GC-MS separation and characterization technique was used to investigate 
volatile compounds in the fractions, however, some new, non-volatile compounds might be 
found in the fractions as neuron protectors. So that, in order to characterize non-volatile 
compounds, other non-volatile detecting analytical method would be recommended such as 
Liquid Chromatography coupled with Mass Spectrometry (LC-MS). 
To the best of our knowledge and based on reports of previous publications that address metal 
chelating activity of microalgae, there are no reports on the new source of neuroprotective 






 of Porphyridium sp. and S. 
costatum. The results of nine species with calcium chelating activity were documented for the 
first time. However, the identified compounds were already reported and characterized by 
NIST. Thus, Porphyridium sp. and S. costatum couldn‟t be a promising source of new-
compounds for the application of pharmaceutical drug formulation. Since, pharmaceutical 
industries dreadfully investigate for a new drug candidate that have not been previously 
identified and characterized by NIST library. Still, countless unexplored bioactive compounds 
from marine microalgae have been gaining great attention due to its potential as novel 
bioactive compounds. As a result, scientists have been investigating new bio-active 
compounds. Other species have been considered to have neuroprotective capacity apart from 












Overall results indicate that microalgae extracts are potentially valuable sources of 
neuroprotective compounds in terms of copper, iron and calcium chelating agents, which 
provide a new insight into their use as a source of therapeutic compounds for metal-induced 
neurodegenerative disease such as AD. According to results, Porphyridium sp. and S. costatum 
are promising strains for natural products of new neuroprotective agents for designing as a good 
alternative ingredients in pharmaceuticals industries and including in the nutrition industries, in 
order to prevent and treat cation-induced neurodegenerative diseases specially Alzheimer‟s.  
A successful GC-MS analysis has done for hexane fractions about 19 and 22 volatile 
compounds with 95.7% of Porphyridium sp. and 92.1% of S. costatum confirmed using NIST 
library respectively. In this study, many biologically beneficial compound groups were 
identified such as long chain saturated and unsaturated (mono and poly) fatty acids, ether, 
alcohols and sterols. Among those, hexadecanoic acid (27.8%); 5,8,11,14-eicosatetraenoic acid 
(13.4%); 5,8,11,14,17-eicosapentaenoic acid (7.29%) and 9,12-octadecadienoic acid (7.22); and 
tetradecanoic acid (31.7%), 9-hexadecenoic acid (21.9%), hexadecanoic acid (12.9%) were 
found to be the most promising.  
The plotted chromatograms, spectra and the structure of most abundant compounds that were 
tentatively identified from hexane fraction from ethanol extract of Porphyridium sp. and S. 













6. PERSPECTIVES FOR FUTURE STUDIES 
Due to a matter of time, Cu
2+
CA of water extract from Isochrysis sp. and Ca
2+
CA of ethyl 
acetate extract from S. costatum were not been further investigated. Results suggested that water 
extract from Isochrysis sp. seems selective towards Cu
2+
CA with an IC50 value of 1.84 mg/mL 
and it is not active in chelating Ca
2+
 whereas less active towards Fe
2+
 with an IC50 = 4.43 
mg/mL. Ethyl acetate extract of S. costatum was significantly active in chelating Ca
2+ 
with an 
IC50 = 1.45 mg/mL than Cu
2+
CA with an IC50 = 4.87 mg/mL and reduced efficacy to chelate 
Fe
2+
. Therefore, both extracts of algae could be a source to design selective-capturing 
biomolecules for the pharmaceutical industries and the production of food supplements. Water 
extract of Isochrysis sp. showed as selective copper chelator and ethyl acetate extract of S. 
costatum showed as selective calcium chelator. 
It has been stated that, cation chelator should possess high enough selectivity to remove the 
targeted metal ion excluding other interference in specific extracts, basically by those essential 
metal ions which are present in significant concentrations
44
. For this reason, both needed to be 
fractionated and re-tested to evaluate their cation-selective chelating ability. If their fractions 
maintain their selective ability, it would be recommended to separate, characterize it in order to 
investigate, to point out in charged specific compounds and to design cation-selective-induced 
neurodegenerative disease like Alzheimer‟s.  
Porphyridium sp. and S. costatum were not selective towards each chelating activity, in other 
hand both are active in chelating copper, iron and calcium with approximately low range of 
variation of concentration, which was one of the drawbacks of synthetic metal chelators (EDTA 




Moreover, hexane fractions of Porphyridium sp. and S. costatum should be re-fractionated, in 
order to obtain concentrated and limited active compounds. Therefore, further studies still 
needed to isolate specific bioactive compounds and then reconfirming of the sub-fractions to 
their neuroprotective properties in terms of copper, iron and calcium chelation. 
In this study, only volatile compounds were identified using GC-MS however non-volatile 
compounds should be identified using another method such as LC-MS in order to search for 
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Annex 1: Tentatively identified the most abundant compounds detected in hexane fraction of 
ethanol extract from Phaeodactylum sp. by GC-MS  
Note: All presented compounds in the Annex are identified derivatives compounds using       
GC-MS, without replacement of hydrogen in place of methyl group.  
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  9,12-Octadecadienoic acid (Z,Z)-, methyl ester (C19H34O2) 
 
Annex 2: Identified most abundant compounds present in hexane fraction of Ethanol extract 
from Skeletonema costatum using GC-MS  
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